Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase M27.002: bontoxilysin

Summary Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: S Structure, A Assay, T Target, P Specificity, K Knockout, E Expression, V Review, I Inhibitor, L Localization, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

    2025
  1. Gao,L., Nowakowska,M.B., Selby,K., Przykopanski,A., Chen,B., Kruger,M., Douillard,F.P., Lam,K.H., Chen,P., Huang,T., Minton,N.P., Dorner,M.B., Dorner,B.G., Rummel,A., Lindstrom,M. and Jin,R.
    Botulinum neurotoxins exploit host digestive proteases to boost their oral toxicity via activating OrfXs/P47
    Nat Struct Mol Biol PubMed  Europe PubMed DOI
  2. Kumar,R. and Singh,B.R.
    Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action
    Int J Mol Sci26, PubMed  Europe PubMed DOI  V
  3. Lalaurie,C.J., Zloh,M., Higazi,D.R., Bunting,K.A. and Dalby,P.A.
    Inter-Domain interactions Slow BoNT/A's onset of action
    J Struct Biol217, 108171-108171. PubMed  Europe PubMed DOI
  4. Lin,M., Karadkhelkar,N., Li,Y., Eubanks,L.M., Tepp,W.H., Pellett,S. and Janda,K.D.
    Bifunctional Inhibition of Botulinum Neurotoxin A Protease: Unexpected Active Site Inhibition Enhances Covalent Targeting of an Allosteric Site
    J Med Chem68, 8796-8816. PubMed  Europe PubMed DOI
  5. Malik,S., Le,L., Boissy,R.E., Brideau-Andersen,A. and Sondergaard,B.
    Botulinum neurotoxin type DC (BoNT/DC) cleavage of VAMP3 reduces melanin production in melanocytes
    Toxicon261, 108372-108372. PubMed  Europe PubMed DOI  K
  6. Sondermann,P., Diercks,C.S., Rong,C. and Schultz,P.G.
    Targeted degradation of alpha-Synuclein using an evolved botulinum toxin protease
    Proc Natl Acad Sci U S A122, e2426745122-e2426745122. PubMed  Europe PubMed DOI
  7. Van Trinh,T., Nguyen,D.V., Hoang,H.D., Pham,H.V., Ngoc Vu,D., Le,P.V., Le,D.N., Vo,C.V. and Le,L.A.T.
    Development and selection of candidate monoclonal antibodies for the detection of Clostridium botulinum neurotoxin serotype B light chain
    Protein Expr Purif228, 106659-106659. PubMed  Europe PubMed DOI
  8. Wang,Y., Zhang,B., Zhang,R., Ding,D., Ma,W., Wang,W., Liu,Z., Zhu,Y., Wang,X., Zhi,D. and Wang,D.
    EGFP/RFP-based FRET sensors for botulinum neurotoxin A biological activity detection and methodological validation
    Anal Chim Acta1337, 343546-343546. PubMed  Europe PubMed DOI
  9. Zhang,Y., Yang,L., Wang,H., Zhang,H., Feng,Y. and Tan,T.
    High-efficiency heterologous expression of functional RVG29-BoNT/A light chain fusion protein in Bacillus subtilis based on a combinatorial strategy
    Int J Biol Macromol310, 143226-143226. PubMed  Europe PubMed DOI  K
    10. 2024
  10. Avelar,R.
    Botulinum Toxin Accessory Proteins: Are They Just an Accessory?
    Dermatol Surg50, S38-S41. PubMed  Europe PubMed DOI  V
  11. Buzzatto,M.V., Benegas Guerrero,F.C., Alvarez,P.A., Zizzias,M.P., Polo,L.M. and Tomes,C.N.
    EXPRESSION, PURIFICATION AND APPLICATION OF A RECOMBINANT, MEMBRANE PERMEATING VERSION OF THE LIGHT CHAIN OF BOTULINUM TOXIN B
    Biosci Rep44, BSR20240117-BSR20240117. PubMed  Europe PubMed DOI
  12. Caliskan,C., Simsek,D., Leese,C., Doran,C., Seward,E., Peden,A.A. and Davletov,B.
    A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A
    ALTEX41, 605-616. PubMed  Europe PubMed DOI
  13. Dong,J., Helveston,E.M. and Hanke,C.W.
    The 200-Year Timeline on Botulinum Toxin: From Biologic Poison to Wonder Drug
    J Drugs Dermatol23, 1357-1359. PubMed  Europe PubMed DOI
  14. Gregg,B.M., Gupta,S., Tepp,W.H. and Pellett,S.
    Expression of Recombinant Clostridial Neurotoxin by C. tetani
    Microorganisms12, PubMed  Europe PubMed DOI
  15. Hoyt,K.M., Barr,J.R., Hopkins,A.O., Dykes,J.K., Luquez,C. and Kalb,S.R.
    Validation of a clinical assay for botulinum neurotoxins through mass spectrometric detection
    J Clin Microbiole0162923-e0162923. PubMed  Europe PubMed DOI
  16. Jeffery,I.A. and Karim,S.
    Botulism
     PubMed  Europe PubMed
  17. Koc,D., Ibis,K., Besarat,P., Banoglu,E. and Kiris,E.
    Tirbanibulin (KX2-391) analog KX2-361 inhibits botulinum neurotoxin serotype A mediated SNAP-25 cleavage in pre- and post-intoxication models in cells
    Drug Dev Res85, e22248-e22248. PubMed  Europe PubMed DOI  I
  18. Majou,D.
    Endopeptidase activities of Clostridium botulinum toxins in the development of this bacterium
    Res Microbiol104216-104216. PubMed  Europe PubMed DOI
  19. Martin,V., Carre,D., Bilbault,H., Oster,S., Limana,L., Sebal,F., Favre-Guilmard,C., Kalinichev,M., Leveque,C., Boulifard,V., George,C. and Lezmi,S.
    Intramuscular Botulinum Neurotoxin Serotypes E and A Elicit Distinct Effects on SNAP25 Protein Fragments, Muscular Histology, Spread and Neuronal Transport: An Integrated Histology-Based Study in the Rat
    Toxins (Basel)16, PubMed  Europe PubMed DOI
  20. Silkina,M.V., Kartseva,A.S., Riabko,A.K., Makarova,M.A., Rogozin,M.M., Romanenko,Y.O., Shemyakin,I.G., Dyatlov,I.A. and Firstova,V.V.
    New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A
    Bioimpacts14, 27680-27680. PubMed  Europe PubMed DOI
  21. Zhou,X., Qi,M. and Yang,M.
    Detection of botulinum neurotoxin A (BoNT/A) enzymatic activity by pregnancy test strips based on hCG-modified magnetic nanoparticles
    Mikrochim Acta191, 114-114. PubMed  Europe PubMed DOI
    22. 2023
  22. Cotter,L., Yu,F., Roqueviere,S., Duchesne de Lamotte,J., Krupp,J., Dong,M. and Nicoleau,C.
    Split luciferase-based assay to detect botulinum neurotoxins using hiPSC-derived motor neurons
    Commun Biol6, 122-122. PubMed  Europe PubMed DOI
  23. Li,Z., Li,B., Lu,J., Liu,X., Tan,X., Wang,R., Du,P., Yu,S., Xu,Q., Pang,X., Yu,Y. and Yang,Z.
    Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F
    Toxins (Basel)15, PubMed  Europe PubMed DOI
  24. Lin,L., Patel,E.N., Nielsen,A.L., Turner,L.D., Tepp,W.H., Nguyen,K., Pellett,S. and Janda,K.
    Transformation of a Metal Chelate into a "Catch and Anchor" Inhibitor of Botulinum A Protease
    Int J Mol Sci24, PubMed  Europe PubMed DOI  I
  25. Liu,Z., Lee,P.G., Krez,N., Lam,K.H., Liu,H., Przykopanski,A., Chen,P., Yao,G., Zhang,S., Tremblay,J.M., Perry,K., Shoemaker,C.B., Rummel,A., Dong,M. and Jin,R.
    Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2
    Nat Commun14, 2338-2338. PubMed  Europe PubMed DOI
  26. Rawson,A.M., Dempster,A.W., Humphreys,C.M. and Minton,N.P.
    Pathogenicity and virulence of Clostridium botulinum
    Virulence14, 2205251-2205251. PubMed  Europe PubMed DOI
  27. Smith,T.J., Schill,K.M. and Williamson,C.H.D.
    Navigating the Complexities Involving the Identification of Botulinum Neurotoxins (BoNTs) and the Taxonomy of BoNT-Producing Clostridia
    Toxins (Basel)15, PubMed  Europe PubMed DOI
  28. Tan,X., Zhang,C.C., Lu,J.S., Li,Z.Y., Li,B.L., Liu,X.Y., Yu,Y.Z. and Xu,Q.
    Biology activity and characterization of the functional L-HN fragment derivative of botulinum neurotoxin serotype E
    Anaerobe82, 102764-102764. PubMed  Europe PubMed DOI
    29. 2022
  29. Cleveland,J.D., Taslimi,A., Liu,Q., Van Keuren,A.M., Churchill,M.E.A. and Tucker,C.L.
    Reprogramming the Cleavage Specificity of Botulinum Neurotoxin Serotype B1
    ACS Synth Biol11, 3318-3329. PubMed  Europe PubMed DOI
  30. Dyer,R.P., Isoda,H.M., Salcedo,G.S., Speciale,G., Fletcher,M.H., Le,L.Q., Liu,Y., Brami-Cherrier,K., Malik,S.Z., Vazquez-Cintron,E.J., Chu,A.C., Rupp,D.C., Jacky,B.P.S., Nguyen,T.T.M., Katz,B.B., Steward,L.E., Majumdar,S., Brideau-Andersen,A.D. and Weiss,G.A.
    Reengineering the specificity of the highly selective Clostridium botulinum protease via directed evolution
    Sci Rep12, 9956-9956. PubMed  Europe PubMed DOI
  31. Fabris,F., Sostaric,P., Matak,I., Binz,T., Toffan,A., Simonato,M., Montecucco,C., Pirazzini,M. and Rossetto,O.
    Detection of VAMP Proteolysis by Tetanus and Botulinum Neurotoxin Type B In Vivo with a Cleavage-Specific Antibody
    Int J Mol Sci23, PubMed  Europe PubMed DOI
  32. Kumar,D.N., Baider,Z., Elad,D., Blum,S.E. and Shtenberg,G.
    Botulinum Neurotoxin C Dual Detection through Immunological Recognition and Endopeptidase Activity Using Porous Silicon Interferometers
    Anal Chem94, 5927-5936. PubMed  Europe PubMed DOI
  33. Lam,K.H., Tremblay,J.M., Perry,K., Ichtchenko,K., Shoemaker,C.B. and Jin,R.
    Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies
    PLoS Pathog18, e1010169-e1010169. PubMed  Europe PubMed DOI
  34. Liu,J., Xu,S., Huang,C., Shen,J., Yu,S., Yu,Y., Sun,Q. and Dai,Q.
    Synthesis and activity evaluation of selenazole-coupled CPI-1 irreversible bifunctional inhibitors for botulinum toxin A light chain
    Bioorg Med Chem Lett73, 128913-128913. PubMed  Europe PubMed DOI  I
  35. Patel,E.N., Turner,L.D., Hixon,M.S. and Janda,K.D.
    Identification of Slow-Binding Inhibitors of the BoNT/A Protease
    ACS Med Chem Lett13, 742-747. PubMed  Europe PubMed DOI
    36. 2021
  36. Ahsanuddin,S., Roy,S., Nasser,W., Povolotskiy,R. and Paskhover,B.
    Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database
    Aesthetic Plast Surg45, 1201-1209. PubMed  Europe PubMed DOI  V
  37. Amezcua,M., Cruz,R.S., Ku,A., Moran,W., Ortega,M.E. and Salzameda,N.T.
    Discovery of Dipeptides as Potent Botulinum Neurotoxin A Light-Chain Inhibitors
    ACS Med Chem Lett12, 295-301. PubMed  Europe PubMed DOI  I
  38. Andreou,A.P., Leese,C., Greco,R., Demartini,C., Corrie,E., Simsek,D., Zanaboni,A., Koroleva,K., Lloyd,J.O., Lambru,G., Doran,C., Gafurov,O., Seward,E., Giniatullin,R., Tassorelli,C. and Davletov,B.
    Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine
    Neurotherapeutics18, 556-568. PubMed  Europe PubMed DOI
  39. Blum,T.R., Liu,H., Packer,M.S., Xiong,X., Lee,P.G., Zhang,S., Richter,M., Minasov,G., Satchell,K.J.F., Dong,M. and Liu,D.R.
    Phage-assisted evolution of botulinum neurotoxin proteases with reprogrammed specificity
    Science371, 803-810. PubMed  Europe PubMed DOI
  40. Dong,M. and Stenmark,P.
    The structure and classification of Botulinum toxins
    Handb Exp Pharmacol263, 11-33. PubMed  Europe PubMed DOI
  41. Gardner,A., Tepp,W.H., Bradshaw,M., Barbieri,J.T. and Pellett,S.
    Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane
    Int J Mol Sci22, PubMed  Europe PubMed DOI
  42. Lin,L., Turner,L.D., Silhar,P., Pellett,S., Johnson,E.A. and Janda,K.D.
    Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A
    RSC Med Chem12, 137-143. PubMed  Europe PubMed DOI
  43. Patel,K.B., Kononova,O., Cai,S., Barsegov,V., Parmar,V.S., Kumar,R. and Singh,B.R.
    Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design
    Biochim Biophys Acta Gen Subj1865, 129933-129933. PubMed  Europe PubMed DOI  I
  44. Song,F., Shen,Y., Wei,Y., Yang,C., Ge,X., Wang,A., Li,C., Wan,Y. and Li,J.
    Botulinum toxin as an ultrasensitive reporter for bacterial and SARS-CoV-2 nucleic acid diagnostics
    Biosens Bioelectron176, 112953-112953. PubMed  Europe PubMed DOI
  45. Stenmark,P.
    Re-engineering Botox
    Science371, 782-782. PubMed  Europe PubMed DOI
  46. Tevell Aberg,A., Karlsson,I. and Hedeland,M.
    Modification and validation of the Endopep-mass spectrometry method for botulinum neurotoxin detection in liver samples with application to samples collected during animal botulism outbreaks
    Anal Bioanal Chem413, 345-354. PubMed  Europe PubMed DOI
  47. Turner,L.D., Nielsen,A.L., Lin,L., Campedelli,A.J., Silvaggi,N.R., Chen,J.S., Wakefield,A.E., Allen,K.N. and Janda,K.D.
    Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease
    ACS Med Chem Lett12, 1318-1324. PubMed  Europe PubMed DOI
  48. Xu,D., Zhang,D.S., Hu,X.F. and Hu,M.Y.
    Evaluation of the efficiency and safety of botulinum toxin A injection on improving facial scars: A protocol for systematic review and meta-analysis
    Medicine (Baltimore)100, e23034-e23034. PubMed  Europe PubMed DOI
    49. 2020
  49. Akpinar,O., Ozsimsek,A., Guzel,M. and Naziroglu,M.
    Clostridium botulinum neurotoxin A induces apoptosis and mitochondrial oxidative stress via activation of TRPM2 channel signaling pathway in neuroblastoma and glioblastoma tumor cells
    J Recept Signal Transduct Res1-13. PubMed  Europe PubMed DOI
  50. Bae,H., Kim,J., Seo,K.K., Hu,K.S., Kim,S.T. and Kim,H.J.
    Comparison between Conventional Blind Injections and Ultrasound-Guided Injections of Botulinum Toxin Type A into the Masseter: A Clinical Trial
    Toxins (Basel)12, PubMed  Europe PubMed DOI
  51. Behrensdorf-Nicol,H.A., Bonifas,U., Klimek,J., Hanschmann,K.M., Dorner,B.G., Hohenadl,C., Tollner,L., Kegel,B. and Kramer,B.
    Transferability study of the BINACLE (binding and cleavage) assay for in vitro determination of botulinum neurotoxin activity
    Biologicals PubMed  Europe PubMed DOI
  52. Bekkers,S., van Ulsen,K.J., Adang,M.M., Scheffer,R.T. and van den Hoogen,J.A.
    Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial
    Dev Med Child Neurol PubMed  Europe PubMed DOI
  53. Bensen,G.P., Rutherford,C.C. and Gardner,T.B.
    Systemic Botulism Toxicity Caused by Pyloric Botox Injection to Treat Gastroparesis
    Case Rep Gastroenterol14, 373-376. PubMed  Europe PubMed DOI
  54. Brunt,J., van Vliet,A.H.M., Carter,A.T., Stringer,S.C., Amar,C., Grant,K.A., Godbole,G. and Peck,M.W.
    Diversity of the Genomes and Neurotoxins of Strains of Clostridium botulinum Group I and Clostridium sporogenes Associated with Foodborne, Infant and Wound Botulism
    Toxins (Basel)12, PubMed  Europe PubMed DOI
  55. Cachero,S., Gkantia,M., Bates,A.S., Frechter,S., Blackie,L., McCarthy,A., Sutcliffe,B., Strano,A., Aso,Y. and Jefferis,G.S.X.E.
    BAcTrace, a tool for retrograde tracing of neuronal circuits in Drosophila
    Nat Methods PubMed  Europe PubMed DOI
  56. Eleopra,R., Rinaldo,S., Montecucco,C., Rossetto,O. and Devigili,G.
    Clinical duration of action of different botulinum toxin types in humans
    Toxicon179, 84-91. PubMed  Europe PubMed DOI
  57. Hasan,F.
    Manufacturing and clinical formulations of Botulinum neurotoxins
    Handb Exp Pharmacol PubMed  Europe PubMed DOI
  58. Klisara,N., Palaniappan,A. and Liedberg,B.
    Sorbent-incorporated dipstick for direct assaying of proteases
    Anal Bioanal Chem412, 1385-1393. PubMed  Europe PubMed DOI  A
  59. Kohda,T., Tsukamoto,K., Torii,Y., Kozaki,S. and Mukamoto,M.
    Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells
    Microbiol Immunol PubMed  Europe PubMed DOI
  60. Kotteduwa Jayawarden,S., Sandarage,R., Farag,J., Ganzert,C., Winston,P., Mills,P. and Reebye,R.
    Effect of treating elbow flexor spasticity with botulinum toxin injection and adjunctive casting on hemiparetic gait parameters: A prospective case series
    J Rehabil Med52, jrm00110-jrm00110. PubMed  Europe PubMed DOI
  61. Kumar,R., Maksudov,F., Kononova,O., Marx,K.A., Barsegov,V. and Singh,B.R.
    Botulinum Endopeptidase: SAXS Experiments and MD Simulations Reveal Extended Solution Structures That Account for Its Biochemical Properties
    J Phys Chem B124, 5801-5812. PubMed  Europe PubMed DOI
  62. Matsumura,T., Amatsu,S., Misaki,R., Yutani,M., Du,A., Kohda,T., Fujiyama,K., Ikuta,K. and Fujinaga,Y.
    Fully human monoclonal antibodies effectively neutralizing Botulinum neurotoxin serotype B
    Toxins (Basel)12, PubMed  Europe PubMed DOI
  63. Morscher,M.A., Thomas,M.D., Sahgal,S. and Adamczyk,M.J.
    Onabotulinum toxin type A injection into the triceps unmasks elbow flexion in infant brachial plexus birth palsy: A retrospective observational cohort study
    Medicine (Baltimore)99, e21830-e21830. PubMed  Europe PubMed DOI
  64. Senel,E. and Muslu,U.
    Global Trends of Botulinum Toxin Literature: A Bibliometric Analysis of Botulinum Toxin Publications Between 1975 and 2017
    J Cutan Aesthet Surg13, 95-102. PubMed  Europe PubMed DOI
  65. Sikorra,S., Donald,S., Elliott,M., Schwede,S., Coker,S.F., Kupinski,A.P., Tripathi,V., Foster,K., Beard,M. and Binz,T.
    Engineering an Effective Human SNAP-23 Cleaving Botulinum Neurotoxin A Variant
    Toxins (Basel)12, PubMed  Europe PubMed DOI
  66. Thompson,J.C., Dao,W.T., Ku,A., Rodriguez-Beltran,S.L., Amezcua,M., Palomino,A.Y., Lien,T. and Salzameda,N.T.
    Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors
    Bioorg Med Chem28, 115659-115659. PubMed  Europe PubMed DOI
  67. Wang,L., Ringelberg,C.S. and Singh,B.R.
    Dramatic neurological and biological effects by botulinum neurotoxin type A on SH-SY5Y neuroblastoma cells, beyond the blockade of neurotransmitter release
    BMC Pharmacol Toxicol21, 66-66. PubMed  Europe PubMed DOI
  68. Winner,B.M., Bodt,S.M.L. and McNutt,P.M.
    Special Delivery: Potential Mechanisms of Botulinum Neurotoxin Uptake and Trafficking within Motor Nerve Terminals
    Int J Mol Sci21, PubMed  Europe PubMed DOI
  69. Yershov,D. and Partridge,R.
    Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia
    Prague Med Rep121, 114-117. PubMed  Europe PubMed DOI
  70. Yin,L., Masuyer,G., Zhang,S., Zhang,J., Miyashita,S.I., Burgin,D., Lovelock,L., Coker,S.F., Fu,T.M., Stenmark,P. and Dong,M.
    Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy
    PLoS Biol18, e3000618-e3000618. PubMed  Europe PubMed DOI
    71. 2019
  71. Dong,M., Masuyer,G. and Stenmark,P.
    Botulinum and Tetanus Neurotoxins
    Annu Rev Biochem88, 811-837. PubMed  Europe PubMed DOI  V
  72. Elliott,M., Favre-Guilmard,C., Liu,S.M., Maignel,J., Masuyer,G., Beard,M., Boone,C., Carre,D., Kalinichev,M., Lezmi,S., Mir,I., Nicoleau,C., Palan,S., Perier,C., Raban,E., Zhang,S., Dong,M., Stenmark,P. and Krupp,J.
    Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models
    Sci Adv5, eaau7196-eaau7196. PubMed  Europe PubMed DOI  U
  73. Garland,M., Babin,B.M., Miyashita,S.I., Loscher,S., Shen,Y., Dong,M. and Bogyo,M.
    Covalent modifiers of Botulinum neurotoxin counteract toxin persistence
    ACS Chem Biol14, 76-87. PubMed  Europe PubMed DOI  I
  74. Halpin,J.L., Dykes,J.K., Katz,L., Centurioni,D.A., Perry,M.J., Egan,C.T. and Luquez,C.
    Molecular characterization of Clostridium botulinum harboring the bont/B7 gene
    Foodborne Pathog Dis16, 428-433. PubMed  Europe PubMed DOI
  75. Joussain,C., Le Coz,O., Pichugin,A., Marconi,P., Lim,F., Sicurella,M., Salonia,A., Montorsi,F., Wandosell,F., Foster,K., Giuliano,F., Epstein,A.L. and Aranda Munoz,A.
    Botulinum neurotoxin light chains expressed by defective herpes simplex virus type-1 vectors cleave SNARE proteins and inhibit CGRP release in rat sensory neurons
    Toxins (Basel)11, PubMed  Europe PubMed DOI
  76. Kerscher,M., Wanitphakdeedecha,R., Trindade de Almeida,A., Maas,C. and Frevert,J.
    IncobotulinumtoxinA: a highly purified and precisely manufactured Botulinum neurotoxin type A
    J Drugs Dermatol18, 52-57. PubMed  Europe PubMed  U
  77. Kutschenko,A., Weisemann,J., Kollewe,K., Fiedler,T., Alvermann,S., Boselt,S., Escher,C., Garde,N., Gingele,S., Kaehler,S.B., Karatschai,R., Kruger,T.H.C., Sikorra,S., Tacik,P., Wegner,F., Wollmann,J., Bigalke,H., Wohlfarth,K. and Rummel,A.
    Botulinum neurotoxin serotype D - a potential treatment alternative for BoNT/A and B non-responding patients
    Clin Neurophysiol130, 1066-1073. PubMed  Europe PubMed DOI
  78. Lin,L., Olson,M.E., Eubanks,L.M. and Janda,K.D.
    Strategies to counteract Botulinum neurotoxin A: nature's deadliest biomolecule
    Acc Chem Res52, 2322-2331. PubMed  Europe PubMed DOI  I
  79. Poulain,B. and Popoff,M.R.
    Why are botulinum neurotoxin-producing bacteria so diverse and botulinum neurotoxins so toxic?
    Toxins (Basel)11, PubMed  Europe PubMed DOI
  80. Rossetto,O. and Montecucco,C.
    Tables of toxicity of Botulinum and Tetanus neurotoxins
    Toxins (Basel)11, PubMed  Europe PubMed DOI
  81. Snow,D.M., Riling,K., Kimbler,A., Espinoza,Y., Wong,D., Pham,K., Martinez,Z., Kraus,C.N., Conrad,F., Garcia-Rodriguez,C., Cobb,R.R., Marks,J.D. and Tomic,M.T.
    Safety and pharmacokinetics of a four monoclonal antibody combination against Botulinum C and D neurotoxins
    Antimicrob Agents Chemother63, e01270-19-e01270-19. PubMed  Europe PubMed DOI
  82. von Berg,L., Stern,D., Pauly,D., Mahrhold,S., Weisemann,J., Jentsch,L., Hansbauer,E.M., Muller,C., Avondet,M.A., Rummel,A., Dorner,M.B. and Dorner,B.G.
    Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology
    Sci Rep9, 5531-5531. PubMed  Europe PubMed DOI
  83. von Berg,L., Stern,D., Weisemann,J., Rummel,A., Dorner,M.B. and Dorner,B.G.
    Optimization of SNAP-25 and VAMP-2 cleavage by Botulinum neurotoxin serotypes A-F employing Taguchi design-of-experiments
    Toxins (Basel)11, PubMed  Europe PubMed DOI  A
    84. 2018
  84. Ambrin,G., Kumar,R. and Singh,B.R.
    Differential endopeptidase activity of different forms of type A botulinum neurotoxin: a unique relationship between the size of the substrate and activity of the enzyme
    Toxicon144, 34-41. PubMed  Europe PubMed DOI  A
  85. Benoit,R.M.
    Botulinum neurotoxin diversity from a gene-centered view
    Toxins (Basel)10, PubMed  Europe PubMed DOI
  86. Brunt,J., Carter,A.T., Stringer,S.C. and Peck,M.W.
    Identification of a novel botulinum neurotoxin gene cluster in Enterococcus
    FEBS Lett592, 310-317. PubMed  Europe PubMed DOI
  87. Chauhan,R., Chauhan,V., Rao,M.K., Chaudhary,D., Bhagyawant,S. and Dhaked,R.K.
    High level expression and immunochemical characterization of botulinum neurotoxin type F light chain
    Protein Expr Purif146, 51-60. PubMed  Europe PubMed DOI  E
  88. Davies,J.R., Liu,S.M. and Acharya,K.R.
    Variations in the Botulinum neurotoxin binding domain and the potential for novel therapeutics
    Toxins (Basel)10, PubMed  Europe PubMed DOI
  89. Dressler,D., Pan,L. and Bigalke,H.
    Comparing incobotulinumtoxinA (Xeomin(R)) and onabotulinumtoxinA (Botox(R)): identical potency labelling in the hemidiaphragm assay
    J Neural Transm (Vienna)125, 1351-1354. PubMed  Europe PubMed DOI  A
  90. Feltrup,T.M., Patel,K., Kumar,R., Cai,S. and Singh,B.R.
    A novel role of C-terminus in introducing a functionally flexible structure critical for the biological activity of botulinum neurotoxin
    Sci Rep8, 8884-8884. PubMed  Europe PubMed DOI  S
  91. Garcia-Rodriguez,C., Razai,A., Geren,I.N., Lou,J., Conrad,F., Wen,W.H., Farr-Jones,S., Smith,T.J., Brown,J.L., Skerry,J.C., Smith,L.A. and Marks,J.D.
    A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes
    Toxins (Basel)10, PubMed  Europe PubMed DOI
  92. Gustafsson,R., Zhang,S., Masuyer,G., Dong,M. and Stenmark,P.
    Crystal structure of Botulinum neurotoxin A2 in complex with the human protein receptor SV2C reveals plasticity in receptor binding
    Toxins (Basel)10, PubMed  Europe PubMed DOI  S
  93. Hackett,G., Moore,K., Burgin,D., Hornby,F., Gray,B., Elliott,M., Mir,I. and Beard,M.
    Purification and characterization of recombinant botulinum neurotoxin serotype FA, also known as serotype H
    Toxins (Basel)10, PubMed  Europe PubMed DOI
  94. Konstantinovic,J., Kiris,E., Kota,K.P., Kugelman-Tonos,J., Videnovic,M., Cazares,L.H., Terzic Jovanovic,N., Verbic,T.Z., Andjelkovic,B., Duplantier,A.J., Bavari,S. and Solaja,B.A.
    New steroidal 4-aminoquinolines antagonize botulinum neurotoxin serotype A in mouse embryonic stem cell derived motor neurons in postintoxication model
    J Med Chem61, 1595-1608. PubMed  Europe PubMed DOI  I
  95. Lam,K.H., Sikorra,S., Weisemann,J., Maatsch,H., Perry,K., Rummel,A., Binz,T. and Jin,R.
    Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA
    Pathog Dis76, fty044-fty044. PubMed  Europe PubMed DOI  S
  96. Moritz,M.S., Tepp,W.H., Bradshaw,M., Johnson,E.A. and Pellett,S.
    Isolation and characterization of the novel botulinum neurotoxin A subtype 6
    mSphere3, PubMed  Europe PubMed DOI
  97. Nugent,M., Yusef,Y.R., Meng,J., Wang,J. and Dolly,J.O.
    A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFalpha-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons
    Neuropharmacology138, 257-266. PubMed  Europe PubMed DOI
  98. Pellett,S., Bradshaw,M., Tepp,W.H., Pier,C.L., Whitemarsh,R.C.M., Chen,C., Barbieri,J.T. and Johnson,E.A.
    The light chain defines the duration of action of botulinum toxin serotype A subtypes
    MBio9, PubMed  Europe PubMed DOI
  99. Pellett,S., Tepp,W.H., Lin,G. and Johnson,E.A.
    Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA")
    Toxicon147, 38-46. PubMed  Europe PubMed DOI
  100. Sikorra,S., Skiba,M., Dorner,M.B., Weisemann,J., Weil,M., Valdezate,S., Davletov,B., Rummel,A., Dorner,B.G. and Binz,T.
    Botulinum neurotoxin F subtypes cleaving the VAMP-2 Q(58)(-)K(59) peptide bond exhibit unique catalytic properties and substrate specificities
    Toxins (Basel)10, PubMed  Europe PubMed DOI
  101. Tehran,D.A. and Pirazzini,M.
    Novel botulinum neurotoxins: exploring underneath the iceberg tip
    Toxins (Basel)10, PubMed  Europe PubMed DOI
  102. Zhang,S., Lebreton,F., Mansfield,M.J., Miyashita,S.I., Zhang,J., Schwartzman,J.A., Tao,L., Masuyer,G., Martinez-Carranza,M., Stenmark,P., Gilmore,M.S., Doxey,A.C. and Dong,M.
    Identification of a botulinum neurotoxin-like toxin in a commensal strain of Enterococcus faecium
    Cell Host Microbe23, 169-176. PubMed  Europe PubMed DOI
    103. 2017
  103. Awan,K.H.
    The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions - An evidence based review
    Saudi Pharm J25, 18-24. PubMed  Europe PubMed DOI  U
  104. Bremer,P.T., Pellett,S., Carolan,J.P., Tepp,W.H., Eubanks,L.M., Allen,K.N., Johnson,E.A. and Janda,K.D.
    Metal ions effectively ablate the action of botulinum neurotoxin A
    J Am Chem Soc139, 7264-7272. PubMed  Europe PubMed DOI  I
  105. Bremer,P.T., Adler,M., Phung,C.H., Singh,A.K. and Janda,K.D.
    Newly designed quinolinol inhibitors mitigate the effects of Botulinum neurotoxin A in enzymatic, cell-based and ex vivo assays
    J Med Chem60, 338-348. PubMed  Europe PubMed DOI  I
  106. Burns,J.R., Lambert,G.S. and Baldwin,M.R.
    Insights into the mechanisms by which clostridial neurotoxins discriminate between gangliosides
    Biochemistry56, 2571-2583. PubMed  Europe PubMed DOI
  107. Dhaliwal,H.K., Thiruvanakarasu,N., Kumar,R., Patel,K., Ambrin,G., Cai,S. and Singh,B.R.
    High yield preparation of functionally active catalytic-translocation domain module of Botulinum neurotoxin type A that exhibits uniquely different enzyme kinetics
    Protein J36, 489-501. PubMed  Europe PubMed DOI  E
  108. Elliott,M., Maignel,J., Liu,S.M., Favre-Guilmard,C., Mir,I., Farrow,P., Hornby,F., Marlin,S., Palan,S., Beard,M. and Krupp,J.
    Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems
    PLoS ONE12, e0185628-e0185628. PubMed  Europe PubMed DOI
  109. Halpin,J.L., Hill,K., Johnson,S.L., Bruce,D.C., Shirey,T.B., Dykes,J.K. and Luquez,C.
    Finished whole-genome sequence of Clostridium argentinense producing botulinum neurotoxin type G
    Genome Announc5, PubMed  Europe PubMed DOI
  110. Harrell,W.A., Jr., Vieira,R.C., Ensel,S.M., Montgomery,V., Guernieri,R., Eccard,V.S., Campbell,Y., Roxas-Duncan,V., Cardellina,J.H.2., Webb,R.P. and Smith,L.A.
    A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A
    Bioorg Med Chem Lett27, 675-678. PubMed  Europe PubMed DOI  I
  111. Jacobson,A.R., Adler,M., Silvaggi,N.R., Allen,K.N., Smith,G.M., Fredenburg,R.A., Stein,R.L., Park,J.B., Feng,X., Shoemaker,C.B., Deshpande,S.S., Goodnough,M.C., Malizio,C.J., Johnson,E.A., Pellett,S., Tepp,W.H. and Tzipori,S.
    Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A
    Toxicon137, 36-47. PubMed  Europe PubMed DOI  I
  112. Liu,J., Gao,S., Kang,L., Ji,B., Xin,W., Kang,J., Li,P., Gao,J., Wang,H., Wang,J. and Yang,H.
    An ultrasensitive gold nanoparticle-based lateral flow test for the detection of active botulinum neurotoxin type A
    Nanoscale Res Lett12, 227-227. PubMed  Europe PubMed DOI  A
  113. Minnow,Y.V., Goldberg,R., Tummalapalli,S.R., Rotella,D.P. and Goodey,N.M.
    Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds
    Arch Biochem Biophys618, 15-22. PubMed  Europe PubMed DOI  I
  114. Olbrich,K., Costard,L., Moser,C.V., Syhr,K.M., King-Himmelreich,T.S., Wolters,M.C., Schmidtko,A., Geisslinger,G. and Niederberger,E.
    Cleavage of SNAP-25 ameliorates cancer pain in a mouse model of melanoma
    Eur J Pain21, 101-111. PubMed  Europe PubMed DOI  U
  115. Patel,K., Halevi,S., Melman,P., Schwartz,J., Cai,S. and Singh,B.R.
    A novel surface plasmon resonance biosensor for the rapid detection of botulinum neurotoxins
    Biosensors (Basel)7, PubMed  Europe PubMed DOI  A
  116. Peck,M.W., Smith,T.J., Anniballi,F., Austin,J.W., Bano,L., Bradshaw,M., Cuervo,P., Cheng,L.W., Derman,Y., Dorner,B.G., Fisher,A., Hill,K.K., Kalb,S.R., Korkeala,H., Lindstrom,M., Lista,F., Luquez,C., Mazuet,C., Pirazzini,M., Popoff,M.R., Rossetto,O., Rummel,A., Sesardic,D., Singh,B.R. and Stringer,S.C.
    Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature
    Toxins (Basel)9, PubMed  Europe PubMed DOI
  117. Rosen,O., Feldberg,L., Dor,E., Gura,S. and Zichel,R.
    Optimization of SNAP-25-derived peptide substrate for improved detection of botulinum A in the Endopep-MS assay
    Anal Biochem528, 34-37. PubMed  Europe PubMed DOI  A
  118. Rust,A., Doran,C., Hart,R., Binz,T., Stickings,P., Sesardic,D., Peden,A.A. and Davletov,B.
    A cell line for detection of botulinum neurotoxin type B
    Front Pharmacol8, 796-796. PubMed  Europe PubMed DOI  A
  119. Scheps,D., Lopez de la Paz,M., Jurk,M., Hofmann,F. and Frevert,J.
    Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action
    Toxicon139, 101-108. PubMed  Europe PubMed DOI
  120. Sorouri,R., Bagheri,H., Afkhami,A. and Salimian,J.
    Fabrication of a novel highly sensitive and selective immunosensor for botulinum neurotoxin serotype A based on an effective platform of electrosynthesized gold nanodendrites/chitosan nanoparticles
    Sensors (Basel)17, PubMed  Europe PubMed DOI  A
  121. Tao,L., Peng,L., Berntsson,R.P., Liu,S.M., Park,S., Yu,F., Boone,C., Palan,S., Beard,M., Chabrier,P.E., Stenmark,P., Krupp,J. and Dong,M.
    Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
    Nat Commun8, 53-53. PubMed  Europe PubMed DOI
  122. Wang,D., Baudys,J., Hoyt,K.M., Barr,J.R. and Kalb,S.R.
    Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry
    Anal Bioanal Chem409, 4779-4786. PubMed  Europe PubMed DOI  A
  123. Wang,J., Casals-Diaz,L., Zurawski,T., Meng,J., Moriarty,O., Nealon,J., Edupuganti,O.P. and Dolly,O.
    A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain
    Neuropharmacology118, 223-232. PubMed  Europe PubMed DOI  U
  124. Xue,S., Seki,H., Remes,M., Silhar,P. and Janda,K.
    Examination of alpha-exosite inhibitors against Botulinum neurotoxin A protease through structure-activity relationship studies of chicoric acid
    Bioorg Med Chem Lett27, 4956-4959. PubMed  Europe PubMed DOI
  125. Yao,G., Lam,K.H., Weisemann,J., Peng,L., Krez,N., Perry,K., Shoemaker,C.B., Dong,M., Rummel,A. and Jin,R.
    A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding
    Sci Rep7, 7438-7438. PubMed  Europe PubMed DOI
  126. Zhang,S., Masuyer,G., Zhang,J., Shen,Y., Lundin,D., Henriksson,L., Miyashita,S.I., Martinez-Carranza,M., Dong,M. and Stenmark,P.
    Identification and characterization of a novel botulinum neurotoxin
    Nat Commun8, 14130-14130. PubMed  Europe PubMed DOI
    127. 2016
  127. Bremer,P.T., Xue,S. and Janda,K.D.
    Picolinic acids as beta-exosite inhibitors of botulinum neurotoxin A light chain
    Chem Commun (Camb)52, 12521-12524. PubMed  Europe PubMed DOI  I
  128. Chang,T.W., Janardhanan,P., Mello,C.M., Singh,B.R. and Cai,S.
    Selection of RNA aptamers against botulinum neurotoxin type A light chain through a non-radioactive approach
    Appl Biochem Biotechnol180, 10-25. PubMed  Europe PubMed DOI  I
  129. Chen,S. and Barbieri,J.T.
    Solubility of the catalytic domains of Botulinum neurotoxin serotype E subtypes
    Protein Expr Purif118, 18-24. PubMed  Europe PubMed DOI  E
  130. Derman,Y., Selby,K., Miethe,S., Frenzel,A., Liu,Y., Rasetti-Escargueil,C., Avril,A., Pelat,T., Urbain,R., Fontayne,A., Thullier,P., Sesardic,D., Lindstrom,M., Hust,M. and Korkeala,H.
    Neutralization of Botulinum neurotoxin type E by a humanized antibody
    Toxins (Basel)8, PubMed  Europe PubMed DOI
  131. Dutta,S.R., Passi,D., Singh,M., Singh,P., Sharma,S. and Sharma,A.
    Botulinum toxin the poison that heals: a brief review
    Natl J Maxillofac Surg7, 10-16. PubMed  Europe PubMed DOI  V
  132. Fan,Y., Barash,J.R., Lou,J., Conrad,F., Marks,J.D. and Arnon,S.S.
    Immunological characterization and neutralizing ability of monoclonal antibodies directed against botulinum neurotoxin type H
    J Infect Dis213, 1606-1614. PubMed  Europe PubMed DOI
  133. Guo,J., Chan,E.W. and Chen,S.
    Comparative characterization of botulinum neurotoxin subtypes F1 and F7 featuring differential substrate recognition and cleavage mechanisms
    Toxicon111, 77-85. PubMed  Europe PubMed DOI
  134. Guo,J., Chan,E.W. and Chen,S.
    Mechanism of substrate recognition by the novel Botulinum neurotoxin subtype F5
    Sci Rep6, 19875-19875. PubMed  Europe PubMed DOI  P
  135. Hansbauer,E.M., Skiba,M., Endermann,T., Weisemann,J., Stern,D., Dorner,M.B., Finkenwirth,F., Wolf,J., Luginbuhl,W., Messelhausser,U., Bellanger,L., Woudstra,C., Rummel,A., Fach,P. and Dorner,B.G.
    Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry
    Analyst141, 5281-5297. PubMed  Europe PubMed DOI
  136. Kolesnikov,A.V., Kozyr,A.V., Ryabko,A.K. and Shemyakin,I.G.
    Ultrasensitive detection of protease activity of anthrax and botulinum toxins by a new PCR-based assay
    Pathog Dis74, ftv112- PubMed  Europe PubMed DOI  A
  137. Kumar,G., Agarwal,R. and Swaminathan,S.
    Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: structure-activity relationship and a pharmacophore model
    Bioorg Med Chem24, 3978-3985. PubMed  Europe PubMed DOI  I
  138. Maslanka,S.E., Luquez,C., Dykes,J.K., Tepp,W.H., Pier,C.L., Pellett,S., Raphael,B.H., Kalb,S.R., Barr,J.R., Rao,A. and Johnson,E.A.
    A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin
    J Infect Dis213, 379-385. PubMed  Europe PubMed DOI
  139. Montecucco,C. and Zanotti,G.
    Botulinum neurotoxin A1 likes it double sweet
    Nat Struct Mol Biol23, 619-621. PubMed  Europe PubMed DOI
  140. Pellett,S., Tepp,W.H., Bradshaw,M., Kalb,S.R., Dykes,J.K., Lin,G., Nawrocki,E.M., Pier,C.L., Barr,J.R., Maslanka,S.E. and Johnson,E.A.
    Purification and characterization of botulinum neurotoxin FA from a genetically modified Clostridium botulinum strain
    mSphere1, PubMed  Europe PubMed DOI
  141. Saffarian,P., Peerayeh,S.N., Amani,J., Ebrahimi,F., Sedighian,H., Halabian,R. and Fooladi,A.A.
    TAT-BoNT/A(1-448) a novel fusion protein as a therapeutic agent: analysis of transcutaneous delivery and enzyme activity
    Appl Microbiol Biotechnol100, 2785-2795. PubMed  Europe PubMed DOI
  142. Sikorra,S., Litschko,C., Muller,C., Thiel,N., Galli,T., Eichner,T. and Binz,T.
    Identification and characterization of botulinum neurotoxin A substrate binding pockets and their re-engineering for human SNAP-23
    J Mol Biol428, 372-384. PubMed  Europe PubMed DOI
  143. Vazquez-Cintron,E., Tenezaca,L., Angeles,C., Syngkon,A., Liublinska,V., Ichtchenko,K. and Band,P.
    Pre-clinical study of a novel recombinant Botulinum neurotoxin derivative engineered for improved safety
    Sci Rep6, 30429-30429. PubMed  Europe PubMed DOI  U
  144. Zhou,Y., McGillick,B.E., Teng,Y.G., Haranahalli,K., Ojima,I., Swaminathan,S. and Rizzo,R.C.
    Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity
    Bioorg Med Chem24, 4875-4889. PubMed  Europe PubMed DOI  I
    145. 2015
  145. Behrensdorf-Nicol,H.A., Weisser,K. and Kramer,B.
    "BINACLE" assay for in vitro detection of active tetanus neurotoxin in toxoids
    ALTEX32, 137-142. PubMed  Europe PubMed DOI  A
  146. Benoit,R.M., Frey,D., Wieser,M.M., Thieltges,K.M., Jaussi,R., Capitani,G. and Kammerer,R.A.
    Structure of the BoNT/A1 - receptor complex
    Toxicon107, 25-31. PubMed  Europe PubMed DOI  S
  147. Carter,A.T. and Peck,M.W.
    Genomes, neurotoxins and biology of Clostridium botulinum Group I and Group II
    Res Microbiol166, 303-317. PubMed  Europe PubMed DOI
  148. Cheng,L.W., Henderson,T.D., Lam,T.I. and Stanker,L.H.
    Use of monoclonal antibodies in the sensitive detection and neutralization of botulinum neurotoxin serotype B
    Toxins (Basel)7, 5068-5078. PubMed  Europe PubMed DOI  A
  149. Fan,Y., Dong,J., Lou,J., Wen,W., Conrad,F., Geren,I.N., Garcia-Rodriguez,C., Smith,T.J., Smith,L.A., Ho,M., Pires-Alves,M., Wilson,B.A. and Marks,J.D.
    Monoclonal antibodies that inhibit the proteolytic activity of botulinum neurotoxin serotype/B
    Toxins (Basel)7, 3405-3423. PubMed  Europe PubMed DOI
  150. Fan,Y., Geren,I.N., Dong,J., Lou,J., Wen,W., Conrad,F., Smith,T.J., Smith,L.A., Ho,M., Pires-Alves,M., Wilson,B.A. and Marks,J.D.
    Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype/A inhibit catalytic activity
    PLoS ONE10, e0135306-e0135306. PubMed  Europe PubMed DOI
  151. Farrow,B., Wong,M., Malette,J., Lai,B., Deyle,K.M., Das,S., Nag,A., Agnew,H.D. and Heath,J.R.
    Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of Botulinum neurotoxin
    Angew Chem Int Ed Engl54, 7114-7119. PubMed  Europe PubMed DOI  I
  152. Guo,J., Wang,J., Gao,S., Ji,B., Waichi Chan,E. and Chen,S.
    Substrate-based inhibitors exhibiting excellent protective and therapeutic effects against Botulinum neurotoxin A intoxication
    Sci Rep5, 16981-16981. PubMed  Europe PubMed DOI  I
  153. Guo,J. and Chen,S.
    Expression and biochemical characterization of light chains of Botulinum neurotoxin subtypes F5 and F7
    Protein Expr Purif111, 87-90. PubMed  Europe PubMed DOI  E
  154. Kalb,S.R., Baudys,J., Raphael,B.H., Dykes,J.K., Luquez,C., Maslanka,S.E. and Barr,J.R.
    Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A)
    Anal Chem87, 3911-3917. PubMed  Europe PubMed DOI
  155. Kalb,S.R., Baudys,J., Wang,D. and Barr,J.R.
    Recommended mass spectrometry-based strategies to identify botulinum neurotoxin-containing samples
    Toxins (Basel)7, 1765-1778. PubMed  Europe PubMed DOI  A
  156. Kalb,S.R., Krilich,J.C., Dykes,J.K., Luquez,C., Maslanka,S.E. and Barr,J.R.
    Detection of botulinum toxins A, B, E, and F in foods by Endopep-MS
    J Agric Food Chem63, 1133-1141. PubMed  Europe PubMed DOI  A
  157. Kostrzewa,R.M., Kostrzewa,R.A. and Kostrzewa,J.P.
    Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview
    Peptides72, 80-87. PubMed  Europe PubMed DOI  V
  158. Kull,S., Schulz,K.M., Strotmeier,J.W., Kirchner,S., Schreiber,T., Bollenbach,A., Dabrowski,P.W., Nitsche,A., Kalb,S.R., Dorner,M.B., Barr,J.R., Rummel,A. and Dorner,B.G.
    Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype
    PLoS ONE10, e0116381-e0116381. PubMed  Europe PubMed DOI
  159. Kumar,G. and Swaminathan,S.
    Recent developments with metalloprotease inhibitor class of drug candidates for botulinum neurotoxins
    Curr Top Med Chem15, 685-695. PubMed  Europe PubMed  I
  160. Kumar,R., Cai,S., Ojadi,E. and Singh,B.R.
    Resolution of sub-nanosecond motions in botulinum neurotoxin endopeptidase: an evidence of internal flexibility
    Biochim Biophys Acta1854, 321-326. PubMed  Europe PubMed DOI
  161. Masuyer,G., Davies,J.R., Moore,K., Chaddock,J.A. and Ravi Acharya,K.
    Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
    Sci Rep5, 13397-13397. PubMed  Europe PubMed DOI  S
  162. Matak,I. and Lackovic,Z.
    Botulinum neurotoxin type A: actions beyond SNAP-25?
    Toxicology335, 79-84. PubMed  Europe PubMed DOI
  163. Montecucco,C. and Rasotto,M.B.
    On botulinum neurotoxin variability
    MBio6, PubMed  Europe PubMed DOI
  164. Montgomery,V.A., Ahmed,S.A., Olson,M.A., Mizanur,R.M., Stafford,R.G., Roxas-Duncan,V.I. and Smith,L.A.
    Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors
    Toxicon98C, 12-19. PubMed  Europe PubMed DOI  I
  165. Park,S., Shin,Y.M., Song,J.J. and Yang,H.
    Facile electrochemical detection of botulinum neurotoxin type E using a two-step proteolytic cleavage
    Biosens Bioelectron72, 211-217. PubMed  Europe PubMed DOI  A
  166. Pellett,S., Tepp,W.H., Whitemarsh,R.C., Bradshaw,M. and Johnson,E.A.
    In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5
    Toxicon107, 37-42. PubMed  Europe PubMed DOI
  167. Rosen,O., Feldberg,L., Gura,S., Brosh-Nissimov,T., Guri,A., Zimhony,O., Shapiro,E., Beth-Din,A., Stein,D., Ozeri,E., Barnea,A., Turgeman,A., Ben David,A., Schwartz,A., Elhanany,E., Diamant,E., Yitzhaki,S. and Zichel,R.
    Early, real-time medical diagnosis of botulism by endopeptidase-mass spectrometry
    Clin Infect Dis61, e58-e61. PubMed  Europe PubMed DOI  A
  168. Rosen,O., Feldberg,L., Gura,S. and Zichel,R.
    A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase-liquid chromatography-tandem mass spectrometry/multiple reaction monitoring assay
    Anal Biochem473, 7-10. PubMed  Europe PubMed DOI  A
  169. Rossetto,O., Pirazzini,M. and Montecucco,C.
    Current gaps in basic science knowledge of botulinum neurotoxin biological actions
    Toxicon107, 59-63. PubMed  Europe PubMed DOI
  170. Savage,A.C., Buckley,N., Halliwell,J. and Gwenin,C.
    Botulinum neurotoxin serotypes detected by electrochemical impedance spectroscopy
    Toxins (Basel)7, 1544-1555. PubMed  Europe PubMed DOI  A
  171. Seki,H., Xue,S., Hixon,M.S., Pellett,S., Remes Combining Breve,M., Johnson,E.A. and Janda,K.D.
    Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity
    Chem Commun (Camb)51, 6226-6229. PubMed  Europe PubMed DOI  I
  172. Smith,T.J., Hill,K.K., Xie,G., Foley,B.T., Williamson,C.H., Foster,J.T., Johnson,S.L., Chertkov,O., Teshima,H., Gibbons,H.S., Johnsky,L.A., Karavis,M.A. and Smith,L.A.
    Genomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genes
    Infect Genet Evol30C, 102-113. PubMed  Europe PubMed DOI
  173. van Uhm,J.I., Visser,G.W., van der Schans,M.J., Geldof,A.A., Meuleman,E.J. and Nieuwenhuijzen,J.A.
    The ultimate radiochemical nightmare: upon radio-iodination of Botulinum neurotoxin A, the introduced iodine atom itself seems to be fatal for the bioactivity of this macromolecule
    EJNMMI Res5, 5-5. PubMed  Europe PubMed DOI
  174. Wang,D., Krilich,J., Baudys,J., Barr,J.R. and Kalb,S.R.
    Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates
    Bioorg Med Chem23, 3667-3673. PubMed  Europe PubMed DOI  A
    175. 2014
  175. Barash,J.R. and Arnon,S.S.
    A novel strain of Clostridium botulinum that produces type B and type H Botulinum toxins
    J Infect Dis209, 183-191. PubMed  Europe PubMed DOI
  176. Bradshaw,M., Tepp,W.H., Whitemarsh,R.C., Pellett,S. and Johnson,E.A.
    Holotoxin activity of botulinum neurotoxin subtype A4 originating from a nontoxigenic Clostridium botulinum expression system
    Appl Environ Microbiol80, 7415-7422. PubMed  Europe PubMed DOI
  177. Bremer,P.T., Hixon,M.S. and Janda,K.D.
    Benzoquinones as inhibitors of botulinum neurotoxin serotype A
    Bioorg Med Chem22, 3971-3981. PubMed  Europe PubMed DOI  I
  178. Caglic,D., Krutein,M.C., Bompiani,K.M., Barlow,D.J., Benoni,G., Pelletier,J.C., Reitz,A.B., Lairson,L.L., Houseknecht,K.L., Smith,G.R. and Dickerson,T.J.
    Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain
    J Med Chem57, 669-676. PubMed  Europe PubMed DOI  I
  179. Dickerson,T.J., Smith,G.R., Pelletier,J.C. and Reitz,A.B.
    8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A
    Curr Top Med Chem14, 2094-2102. PubMed  Europe PubMed  I
  180. Dickerson,T.J., Smith,G.R. and Reitz,A.B.
    Inhibition of botulinum neurotoxin BoNT/A
    Curr Top Med Chem14, 2043-2043. PubMed  Europe PubMed  I
  181. Dolly,J.O. and Lawrence,G.W.
    Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A
    Neurourol Urodyn33 Suppl 3, S14-S20. PubMed  Europe PubMed DOI  V
  182. Dover,N., Barash,J.R., Hill,K.K., Xie,G. and Arnon,S.S.
    Molecular characterization of a novel botulinum neurotoxin type H gene
    J Infect Dis209, 192-202. PubMed  Europe PubMed DOI
  183. Gregory,R.W., Werner,W.E. and Ruegg,C.
    A quantitative bifunctional in vitro potency assay for botulinum neurotoxin serotype A
    J Pharmacol Toxicol Methods69, 103-107. PubMed  Europe PubMed DOI  A
  184. Guo,J., Xu,C., Li,X. and Chen,S.
    A simple, rapid and sensitive FRET assay for Botulinum neurotoxin serotype B detection
    PLoS ONE9, e114124-e114124. PubMed  Europe PubMed DOI  A
  185. Hu,X., Legler,P.M., Southall,N., Maloney,D.J., Simeonov,A. and Jadhav,A.
    Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening
    J Comput Aided Mol Des28, 765-778. PubMed  Europe PubMed DOI  I
  186. Kiris,E., Burnett,J.C., Kane,C.D. and Bavari,S.
    Recent advances in botulinum neurotoxin inhibitor development
    Curr Top Med Chem14, 2044-2061. PubMed  Europe PubMed  I
  187. Kota,K.P., Soloveva,V., Wanner,L.M., Gomba,G., Kiris,E., Panchal,R.G., Kane,C.D. and Bavari,S.
    A high content imaging assay for identification of botulinum neurotoxin inhibitors
    J Vis Expe51915-e51915. PubMed  Europe PubMed DOI  A
  188. Kumar,R., Kukreja,R.V., Li,L., Zhmurov,A., Kononova,O., Cai,S., Ahmed,S.A., Barsegov,V. and Singh,B.R.
    Botulinum neurotoxin: unique folding of enzyme domain of the most-poisonous poison
    J Biomol Struct Dyn32, 804-815. PubMed  Europe PubMed DOI
  189. Kumar,R., Kukreja,R.V., Cai,S. and Singh,B.R.
    Differential role of molten globule and protein folding in distinguishing unique features of botulinum neurotoxin
    Biochim Biophys Acta1844, 1145-1152. PubMed  Europe PubMed DOI
  190. Kwon,S.J., Jeong,E.J., Yoo,Y.C., Cai,C., Yang,G.H., Lee,J.C., Dordick,J.S., Linhardt,R.J. and Lee,K.B.
    High sensitivity detection of active botulinum neurotoxin by glyco-quantitative polymerase chain-reaction
    Anal Chem86, 2279-2284. PubMed  Europe PubMed DOI  A
  191. Leveque,C., Ferracci,G., Maulet,Y., Mazuet,C., Popoff,M., Seagar,M. and El Far,O.
    Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism
    Biosens Bioelectron57, 207-212. PubMed  Europe PubMed DOI  A
  192. Liu,X., Wang,Y., Chen,P., Wang,Y., Zhang,J., Aili,D. and Liedberg,B.
    Biofunctionalized gold nanoparticles for colorimetric sensing of Botulinum neurotoxin A light chain
    Anal Chem86, 2345-2352. PubMed  Europe PubMed DOI  A
  193. Patel,K., Cai,S. and Singh,B.R.
    Current strategies for designing antidotes against botulinum neurotoxins
    Expert Opin Drug Discov9, 319-333. PubMed  Europe PubMed DOI  T
  194. Seki,H., Pellett,S., Silhar,P., Stowe,G.N., Blanco,B., Lardy,M.A., Johnson,E.A. and Janda,K.D.
    Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain
    Bioorg Med Chem22, 1208-1217. PubMed  Europe PubMed DOI  I
  195. Shi,J., Guo,J., Bai,G., Chan,C., Liu,X., Ye,W., Hao,J., Chen,S. and Yang,M.
    A graphene oxide based fluorescence resonance energy transfer (FRET) biosensor for ultrasensitive detection of botulinum neurotoxin A (BoNT/A) enzymatic activity
    Biosens Bioelectron65C, 238-244. PubMed  Europe PubMed DOI  A
  196. Vagin,O., Tokhtaeva,E., Garay,P.E., Souda,P., Bassilian,S., Whitelegge,J.P., Lewis,R., Sachs,G., Wheeler,L., Aoki,R. and Fernandez-Salas,E.
    Recruitment of septin cytoskeletal proteins by Botulinum toxin A protease determines its remarkable stability
    J Cell Sci127, 3294-3308. PubMed  Europe PubMed DOI
  197. Xue,S., Javor,S., Hixon,M.S. and Janda,K.D.
    Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity
    Biochemistry53, 6820-6824. PubMed  Europe PubMed DOI  S
    198. 2013
  198. Bagramyan,K., Kaplan,B.E., Cheng,L.W., Strotmeier,J., Rummel,A. and Kalkum,M.
    Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples
    Anal Chem85, 5569-5576. PubMed  Europe PubMed DOI  A
  199. Bigalke,H.
    Botulinum toxin: application, safety, and limitations
    Curr Top Microbiol Immunol364, 307-317. PubMed  Europe PubMed DOI  U
  200. Binz,T.
    Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission
    Curr Top Microbiol Immunol364, 139-157. PubMed  Europe PubMed DOI  P
  201. Bok,S., Korampally,V., Darr,C.M., Folk,W.R., Polo-Parada,L., Gangopadhyay,K. and Gangopadhyay,S.
    Femtogram-level detection of Clostridium botulinum neurotoxin type A by sandwich immunoassay using nanoporous substrate and ultra-bright fluorescent suprananoparticles
    Biosens Bioelectron41, 409-416. PubMed  Europe PubMed DOI  A
  202. Bryant,A.M., Davis,J., Cai,S. and Singh,B.R.
    Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum Hall A strain
    Protein J32, 106-117. PubMed  Europe PubMed DOI
  203. Caglic,D., Bompiani,K.M., Krutein,M.C., Capek,P. and Dickerson,T.J.
    A high-throughput-compatible FRET-based platform for identification and characterization of Botulinum neurotoxin light chain modulators
    J Vis Exp50908-50908. PubMed  Europe PubMed DOI  A
  204. Dadgar,S., Ramjan,Z. and Floriano,W.B.
    Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A
    J Med Chem56, 2791-2803. PubMed  Europe PubMed DOI  L  I
  205. Dover,N., Barash,J.R., Hill,K.K., Davenport,K.W., Teshima,H., Xie,G. and Arnon,S.S.
    Clostridium botulinum strain Af84 contains three neurotoxin gene clusters: bont/A2, bont/F4 and bont/F5
    PLoS ONE8, e61205-e61205. PubMed  Europe PubMed DOI
  206. Eleopra,R., Montecucco,C., Devigili,G., Lettieri,C., Rinaldo,S., Verriello,L., Pirazzini,M., Caccin,P. and Rossetto,O.
    Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study
    Clin Neurophysiol124, 999-1004. PubMed  Europe PubMed DOI
  207. Guo,J. and Chen,S.
    Unique substrate recognition mechanism of the botulinum neurotoxin D light chain
    J Biol Chem288, 27881-27887. PubMed  Europe PubMed DOI
  208. Halliwell,J. and Gwenin,C.
    A label free colorimetric assay for the detection of active Botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold
    Toxins (Basel)5, 1381-1391. PubMed  Europe PubMed DOI  A
  209. Hawlitschka,A., Antipova,V., Schmitt,O., Witt,M., Benecke,R., Mix,E. and Wree,A.
    Intracerebrally applied Botulinum neurotoxin in experimental neuroscience
    Curr Pharm Biotechnol14, 124-130. PubMed  Europe PubMed  U
  210. Lawrence,G.W., Ovsepian,S.V., Wang,J., Aoki,K.R. and Dolly,J.O.
    Therapeutic effectiveness of botulinum neurotoxin A: Potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25
    Neuropharmacology70, 287-295. PubMed  Europe PubMed DOI  P
  211. Lee,K., Gu,S., Jin,L., Le,T.T., Cheng,L.W., Strotmeier,J., Kruel,A.M., Yao,G., Perry,K., Rummel,A. and Jin,R.
    Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity
    PLoS Pathog9, e1003690-e1003690. PubMed  Europe PubMed DOI  S
  212. Leveque,C., Ferracci,G., Maulet,Y., Grand-Masson,C., Blanchard,M.P., Seagar,M. and El Far,O.
    A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A
    Biosens Bioelectron49, 276-281. PubMed  Europe PubMed DOI  A
  213. Mizanur,R.M., Frasca,V., Swaminathan,S., Bavari,S., Webb,R., Smith,L.A. and Ahmed,S.A.
    The C terminus of the catalytic domain of type A Botulinum neurotoxin may facilitate product release from the active site
    J Biol Chem288, 24223-24233. PubMed  Europe PubMed DOI
  214. Ouimet,T., Duquesnoy,S., Poras,H., Fournie-Zaluski,M.C. and Roques,B.P.
    Comparison of fluorigenic peptide substrates PL50, SNAPtide, and BoTest A/E for BoNT/A detection and quantification: exosite binding confers high-assay sensitivity
    J Biomol Screen18, 726-735. PubMed  Europe PubMed DOI  A
  215. Rossetto,O., Scorzeto,M., Megighian,A. and Montecucco,C.
    Tetanus neurotoxin
    Toxicon66, 59-63. PubMed  Europe PubMed DOI  V
  216. Silhar,P., Silvaggi,N.R., Pellett,S., Capkova,K., Johnson,E.A., Allen,K.N. and Janda,K.D.
    Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studies
    Bioorg Med Chem21, 1344-1348. PubMed  Europe PubMed DOI  I
  217. Silhar,P., Lardy,M.A., Hixon,M.S., Shoemaker,C.B., Barbieri,J.T., Struss,A.K., Lively,J.M., Javor,S. and Janda,K.D.
    The C-terminus of botulinum A protease has profound and unanticipated kinetic consequences upon the catalytic cleft
    ACS Med Chem Lett4, 283-287. PubMed  Europe PubMed DOI
  218. Swaminathan,S.
    Structure-based drug discovery for botulinum neurotoxins
    Curr Top Microbiol Immunol364, 197-218. PubMed  Europe PubMed DOI  I
  219. Wang,D., Krilich,J., Pellett,S., Baudys,J., Tepp,W.H., Barr,J.R., Johnson,E.A. and Kalb,S.R.
    Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5
    Biochim Biophys Acta1834, 2722-2728. PubMed  Europe PubMed DOI  A  P
  220. Wang,D., Baudys,J., Ye,Y., Rees,J.C., Barr,J.R., Pirkle,J.L. and Kalb,S.R.
    Improved detection of botulinum neurotoxin serotype A by Endopep-MS through peptide substrate modification
    Anal Biochem432, 115-123. PubMed  Europe PubMed DOI  A
  221. Whitemarsh,R.C., Tepp,W.H., Bradshaw,M., Lin,G., Pier,C.L., Scherf,J.M., Johnson,E.A. and Pellett,S.
    Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro
    Infect Immun81, 3894-3902. PubMed  Europe PubMed DOI
    222. 2012
  222. Dolly,J.O. and O'Connell,M.A.
    Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain
    Curr Opin Pharmacol12, 100-108. PubMed  Europe PubMed DOI  U
  223. Eichhorn,T., Dolimbek,B.Z., Deeg,K., Efferth,T. and Atassi,M.Z.
    Inhibition invivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening
    Toxicon60, 1180-1190. PubMed  Europe PubMed DOI  I
  224. Feltrup,T.M. and Singh,B.R.
    Development of a fluorescence internal quenching correction factor to correct Botulinum neurotoxin type A endopeptidase kinetics using SNAPtide
    Anal Chem84, 10549-10553. PubMed  Europe PubMed DOI  A
  225. Fernandez-Salas,E., Wang,J., Molina,Y., Nelson,J.B., Jacky,B.P. and Aoki,K.R.
    Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay
    PLoS ONE7, e49516-e49516. PubMed  Europe PubMed DOI  A
  226. Ho,M., Goh,C.H., Brothers,M.C., Wang,S., Young,R.L., Ou,Y., Lui,J.N., Kalafatis,M., Lan,X., Wolf,A.E., Rienstra,C.M. and Wilson,B.A.
    Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A
    Protein Sci21, 318-326. PubMed  Europe PubMed DOI
  227. Joshi,S.G.
    Detection of biologically active botulinum neurotoxin-A in serum using high-throughput FRET-assay
    J Pharmacol Toxicol Methods65, 8-12. PubMed  Europe PubMed DOI  A
  228. Kalb,S.R., Baudys,J., Webb,R.P., Wright,P., Smith,T.J., Smith,L.A., Fernandez,R., Raphael,B.H., Maslanka,S.E., Pirkle,J.L. and Barr,J.R.
    Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5
    FEBS Lett586, 109-115. PubMed  Europe PubMed DOI  P
  229. Kumar,G., Kumaran,D., Ahmed,S.A. and Swaminathan,S.
    Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling
    Acta Crystallogr D Biol Crystallogr68, 511-520. PubMed  Europe PubMed DOI  S  I
  230. Kumar,G., Agarwal,R. and Swaminathan,S.
    Discovery of a fluorene class of compounds as inhibitors of botulinum neurotoxin serotype E by virtual screening
    Chem Commun (Camb)48, 2412-2414. PubMed  Europe PubMed DOI  I
  231. Mizanur,R.M., Gorbet,J., Swaminathan,S. and Ahmed,S.A.
    Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium
    Int J Biochem Mol Biol3, 313-321. PubMed  Europe PubMed  I
  232. Montecucco,C. and Tonello,F.
    Bontoxilysins
    [ISSN:978-0-12-407744-7]3, 660-665. DOI
  233. Opsenica,I., Filipovic,V., Nuss,J.E., Gomba,L.M., Opsenica,D., Burnett,J.C., Gussio,R., Solaja,B.A. and Bavari,S.
    The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease
    Eur J Med Chem53, 374-379. PubMed  Europe PubMed DOI  I
  234. Peng Chen,Z., Morris,J.G., Rodriguez,R.L., Shukla,A.W., Tapia-Nunez,J. and Okun,M.S.
    Emerging opportunities for serotypes of botulinum neurotoxins
    Toxins (Basel)4, 1196-1222. PubMed  Europe PubMed DOI  U
  235. Singh,P., Singh,M.K., Chaudhary,D., Chauhan,V., Bharadwaj,P., Pandey,A., Upadhyay,N. and Dhaked,R.K.
    Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice
    PLoS ONE7, e47110-e47110. PubMed  Europe PubMed DOI  I
  236. Smith,G.R., Caglic,D., Capek,P., Zhang,Y., Godbole,S., Reitz,A.B. and Dickerson,T.J.
    Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the beta-exosite
    Bioorg Med Chem Lett22, 3754-3757. PubMed  Europe PubMed DOI  I
  237. Somm,E., Bonnet,N., Martinez,A., Marks,P.M., Cadd,V.A., Elliott,M., Toulotte,A., Ferrari,S.L., Rizzoli,R., Huppi,P.S., Harper,E., Melmed,S., Jones,R. and Aubert,M.L.
    A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis
    J Clin Invest122, 3295-3306. PubMed  Europe PubMed DOI  U
  238. Stura,E.A., Le Roux,L., Guitot,K., Garcia,S., Bregant,S., Beau,F., Vera,L., Collet,G., Ptchelkine,D., Bakirci,H. and Dive,V.
    Structural framework for covalent inhibition of Clostridium botulinum neurotoxin A by targeting Cys165
    J Biol Chem287, 33607-33614. PubMed  Europe PubMed DOI  S
  239. Tajti,J., Szok,D., Tuka,B., Csati,A., Kuris,A., Majlath,Z., Lukacs,M. and Vecsei,L.
    [Botulinum neurotoxin - a therapy in migraine]
    Ideggyogy Sz65, 77-82. PubMed  Europe PubMed  U
  240. Tepp,W.H., Lin,G. and Johnson,E.A.
    Purification and characterization of a novel subtype a3 botulinum neurotoxin
    Appl Environ Microbiol78, 3108-3113. PubMed  Europe PubMed DOI
  241. Yamamoto,H., Ida,T., Tsutsuki,H., Mori,M., Matsumoto,T., Kohda,T., Mukamoto,M., Goshima,N., Kozaki,S. and Ihara,H.
    Specificity of botulinum protease for human VAMP family proteins
    Microbiol Immunol56, 245-253. PubMed  Europe PubMed DOI  P
  242. Zhao,Y., Kang,L., Gao,S., Gao,X., Xin,W. and Wang,J.
    PEG precipitation coupled with chromatography is a new and sufficient method for the purification of botulinum neurotoxin type B [corrected]
    PLoS ONE7, e39670-e39670. PubMed  Europe PubMed DOI
  243. Zhu,Z., Stone,H.F., Thach,T.Q., Garcia,L. and Ruegg,C.L.
    A novel botulinum neurotoxin topical gel: treatment of allergic rhinitis in rats and comparative safety profile
    Am J Rhinol Allergy26, 450-454. PubMed  Europe PubMed DOI
    244. 2011
  244. Bagramyan,K. and Kalkum,M.
    Ultrasensitive detection of Botulinum neurotoxins and anthrax lethal factor in biological samples by ALISSA
    Methods Mol Biol739, 23-36. PubMed  Europe PubMed DOI  A
  245. Capek,P., Zhang,Y., Barlow,D.J., Houseknecht,K.L., Smith,G.R. and Dickerson,T.J.
    Enhancing the pharmacokinetic properties of botulinum neurotoxin serotype A protease inhibitors through rational design
    ACS Chem Neurosci2, 288-293. PubMed  Europe PubMed DOI  U
  246. Cardellina,J.H., Vieira,R.C., Eccard,V., Skerry,J., Montgomery,V., Campbell,Y., Roxas-Duncan,V., Leister,W., Leclair,C.A., Maloney,D.J., Padula,D., Pescitelli,G., Khavrutskii,I., Hu,X., Wallqvist,A. and Smith,L.A.
    Separation of Betti reaction product enantiomers: absolute configuration and inhibition of Botulinum neurotoxin A
    ACS Med Chem Lett2, 396-401. PubMed  Europe PubMed DOI  I
  247. Chahboun,S., Hust,M., Liu,Y., Pelat,T., Miethe,S., Helmsing,S., Jones,R.G., Sesardic,D. and Thullier,P.
    Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin
    BMC Biotechnol11, 113-113. PubMed  Europe PubMed DOI
  248. Chen,S. and Wan,H.Y.
    Molecular mechanisms of substrate recognition and specificity of Botulinum neurotoxin serotype F
    Biochem J433, 277-284. PubMed  Europe PubMed DOI  P
  249. Ferracci,G., Marconi,S., Mazuet,C., Jover,E., Blanchard,M.P., Seagar,M., Popoff,M. and Leveque,C.
    A label-free biosensor assay for Botulinum neurotoxin B in food and human serum
    Anal Biochem410, 281-288. PubMed  Europe PubMed DOI  A
  250. Ferrari,E., Maywood,E.S., Restani,L., Caleo,M., Pirazzini,M., Rossetto,O., Hastings,M.H., Niranjan,D., Schiavo,G. and Davletov,B.
    Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity
    Toxins (Basel)3, 345-355. PubMed  Europe PubMed DOI
  251. Gilmore,M.A., Williams,D., Okawa,Y., Holguin,B., James,N.G., Ross,J.A., Roger Aoki,K., Jameson,D.M. and Steward,L.E.
    Depolarization after resonance energy transfer (DARET): a sensitive fluorescence-based assay for Botulinum neurotoxin protease activity
    Anal Biochem413, 36-42. PubMed  Europe PubMed DOI  A
  252. Hale,M., Oyler,G., Swaminathan,S. and Ahmed,S.A.
    Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity
    J Biol Chem286, 1802-1811. PubMed  Europe PubMed DOI  I
  253. Jacobson,M.J., Lin,G., Tepp,W., Dupuy,J., Stenmark,P., Stevens,R.C. and Johnson,E.A.
    Purification, modeling, and analysis of Botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222
    Appl Environ Microbiol77, 4217-4222. PubMed  Europe PubMed DOI
  254. Li,B., Peet,N.P., Butler,M.M., Burnett,J.C., Moir,D.T. and Bowlin,T.L.
    Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication
    Molecules16, 202-220. PubMed  Europe PubMed DOI  I
  255. Li,B., Cardinale,S.C., Butler,M.M., Pai,R., Nuss,J.E., Peet,N.P., Bavari,S. and Bowlin,T.L.
    Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors
    Bioorg Med Chem19, 7338-7348. PubMed  Europe PubMed DOI  I
  256. Masuyer,G., Beard,M., Cadd,V.A., Chaddock,J.A. and Acharya,K.R.
    Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B
    J Struct Biol174, 52-57. PubMed  Europe PubMed DOI  S
  257. Masuyer,G., Stancombe,P., Chaddock,J.A. and Acharya,K.R.
    Structures of engineered Clostridium botulinum neurotoxin derivatives
    Acta Crystallogr Sect F Struct Biol Cryst Commun67, 1466-1472. PubMed  Europe PubMed DOI
  258. Piazza,T.M., Blehert,D.S., Dunning,F.M., Berlowski-Zier,B.M., Zeytin,F.N., Samuel,M.D. and Tucker,W.C.
    In vitro detection and quantification of Botulinum neurotoxin type E activity in avian blood
    Appl Environ Microbiol77, 7815-7822. PubMed  Europe PubMed DOI  A
  259. Ross,J.A., Gilmore,M.A., Williams,D., Aoki,K.R., Steward,L.E. and Jameson,D.M.
    Characterization of Forster resonance energy transfer in a Botulinum neurotoxin protease assay
    Anal Biochem413, 43-49. PubMed  Europe PubMed DOI  A
  260. Ruge,D.R., Dunning,F.M., Piazza,T.M., Molles,B.E., Adler,M., Zeytin,F.N. and Tucker,W.C.
    Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters
    Anal Biochem411, 200-209. PubMed  Europe PubMed DOI  A
  261. Ruthel,G., Burnett,J.C., Nuss,J.E., Wanner,L.M., Tressler,L.E., Torres-Melendez,E., Sandwick,S.J., Retterer,C.J. and Bavari,S.
    Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors
    Toxins (Basel)3, 207-217. PubMed  Europe PubMed DOI  I
  262. Salzameda,N.T., Eubanks,L.M., Zakhari,J.S., Tsuchikama,K., Denunzio,N.J., Allen,K.N., Hixon,M.S. and Janda,K.D.
    A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action
    Chem Commun (Camb)47, 1713-1715. PubMed  Europe PubMed DOI  I
  263. Sapsford,K.E., Granek,J., Deschamps,J.R., Boeneman,K., Blanco-Canosa,J.B., Dawson,P.E., Susumu,K., Stewart,M.H. and Medintz,I.L.
    Monitoring Botulinum neurotoxin A activity with peptide-functionalized quantum dot resonance energy transfer sensors
    ACS Nano5, 2687-2699. PubMed  Europe PubMed DOI  A
  264. Swaminathan,S.
    Molecular structures and functional relationships in clostridial neurotoxins
    FEBS J278, 4467-4485. PubMed  Europe PubMed DOI  V  S
  265. Thanongsaksrikul,J. and Chaicumpa,W.
    Botulinum neurotoxins and botulism: a novel therapeutic approach
    Toxins (Basel)3, 469-488. PubMed  Europe PubMed DOI
  266. Thompson,A.A., Jiao,G.S., Kim,S., Thai,A., Cregar-Hernandez,L., Margosiak,S.A., Johnson,A.T., Han,G.W., O'Malley,S. and Stevens,R.C.
    Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility
    Biochemistry50, 4019-4028. PubMed  Europe PubMed DOI  I
  267. Tian,R.M., Li,T., Hou,X.J., Wang,Q., Cai,K., Liu,Y.N., Gao,X., Liu,H., Xiao,L., Tu,W., Shi,J., Cao,W.C. and Wang,H.
    The complete genome sequence of Clostridium botulinum F str. 230613, insertion sites, and recombination of BoNT gene clusters
    Genome54, 546-554. PubMed  Europe PubMed DOI
  268. Wang,J., Zurawski,T.H., Meng,J., Lawrence,G., Olango,W.M., Finn,D.P., Wheeler,L. and Dolly,J.O.
    A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic
    J Biol Chem286, 6375-6385. PubMed  Europe PubMed DOI
  269. Yu,H.M., Li,Q., Zhou,X.D., Perelman,J.M. and Kolosov,V.P.
    Expression of recombinant fusion protein BoNT-LH (N)-elafin in Pichia pastoris and activity of expressed product
    Chin J Biol24, 389-393.  U
    270. 2010
  270. Band,P.A., Blais,S., Neubert,T.A., Cardozo,T.J. and Ichtchenko,K.
    Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery
    Protein Expr Purif71, 62-73. PubMed  Europe PubMed DOI  E
  271. Burnett,J.C., Li,B., Pai,R., Cardinale,S.C., Butler,M.M., Peet,N.P., Moir,D., Bavari,S. and Bowlin,T.
    Analysis of botulinum neurotoxin serotype A metalloprotease inhibitors: analogs of a chemotype for therapeutic development in the context of a three-zone pharmacophore
    Open Access Bioinformatics2010, 11-18. PubMed  Europe PubMed DOI  I
  272. Capkova,K., Hixon,M.S., Pellett,S., Barbieri,J.T., Johnson,E.A. and Janda,K.D.
    Benzylidene cyclopentenediones: first irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase
    Bioorg Med Chem Lett20, 206-208. PubMed  Europe PubMed DOI  I
  273. Carmichael,N.M., Dostrovsky,J.O. and Charlton,M.P.
    Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin
    Pain149, 316-324. PubMed  Europe PubMed DOI  U
  274. Chang,T.W., Blank,M., Janardhanan,P., Singh,B.R., Mello,C., Blind,M. and Cai,S.
    In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin
    Biochem Biophys Res Commun396, 854-860. PubMed  Europe PubMed DOI  I
  275. Conway,J.O., Sherwood,L.J., Collazo,M.T., Garza,J.A. and Hayhurst,A.
    Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents
    PLoS ONE5, e8818-e8818. PubMed  Europe PubMed DOI
  276. Darios,F., Niranjan,D., Ferrari,E., Zhang,F., Soloviev,M., Rummel,A., Bigalke,H., Suckling,J., Ushkaryov,Y., Naumenko,N., Shakirzyanova,A., Giniatullin,R., Maywood,E., Hastings,M., Binz,T. and Davletov,B.
    SNARE tagging allows stepwise assembly of a multimodular medicinal toxin
    Proc Natl Acad Sci U S A107, 18197-18201. PubMed  Europe PubMed DOI  E
  277. Dong,J., Thompson,A.A., Fan,Y., Lou,J., Conrad,F., Ho,M., Pires-Alves,M., Wilson,B.A., Stevens,R.C. and Marks,J.D.
    A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region
    J Mol Biol397, 1106-1118. PubMed  Europe PubMed DOI
  278. Eubanks,L.M., Silhar,P., Salzameda,N.T., Zakhari,J.S., Xiaochuan,F., Barbieri,J.T., Shoemaker,C.B., Hixon,M.S. and Janda,K.D.
    Identification of a natural product antagonist against the botulinum neurotoxin light chain protease
    ACS Med Chem Lett1, 268-272. PubMed  Europe PubMed DOI  I
  279. Gul,N., Smith,L.A. and Ahmed,S.A.
    Light chain separated from the rest of the type A botulinum neurotoxin molecule is the most catalytically active form
    PLoS ONE5, e12872-e12872. PubMed  Europe PubMed DOI
  280. Hakami,R.M., Ruthel,G., Stahl,A.M. and Bavari,S.
    Gaining ground: assays for therapeutics against botulinum neurotoxin
    Trends Microbiol18, 164-172. PubMed  Europe PubMed DOI  I
  281. Hexsel,D., Spencer,J.M., Woolery-Lloyd,H. and Gilbert,E.
    Practical applications of a new botulinum toxin
    J Drugs Dermatol9, s31-s37. PubMed  Europe PubMed  U
  282. Indrawattana,N., Sookrung,N., Kulkeaw,K., Seesuay,W., Kongngoen,T., Chongsa-nguan,M., Tungtrongchitr,A. and Chaicumpa,W.
    Human monoclonal ScFv that inhibits cellular entry and metalloprotease activity of tetanus neurotoxin
    Asian Pac J Allergy Immunol28, 85-93. PubMed  Europe PubMed  I
  283. Kalb,S.R., Garcia-Rodriguez,C., Lou,J., Baudys,J., Smith,T.J., Marks,J.D., Smith,L.A., Pirkle,J.L. and Barr,J.R.
    Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS
    PLoS ONE5, e12237-e12237. PubMed  Europe PubMed DOI  A
  284. Kukreja,R.V., Sharma,S.K. and Singh,B.R.
    Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E
    Biochemistry49, 2510-2519. PubMed  Europe PubMed DOI
  285. Marshall,K.M., Bradshaw,M. and Johnson,E.A.
    Conjugative botulinum neurotoxin-encoding plasmids in Clostridium botulinum
    PLoS ONE5, e11087-e11087. PubMed  Europe PubMed DOI
  286. Montal,M.
    Botulinum neurotoxin: a marvel of protein design
    Annu Rev Biochem79, 591-617. PubMed  Europe PubMed DOI  V
  287. Nuss,J.E., Wanner,L.M., Tressler,L.E. and Bavari,S.
    The osmolyte trimethylamine N-oxide (TMAO) increases the proteolytic activity of Botulinum neurotoxin light chains A, B, and E: implications for enhancing analytical assay sensitivity
    J Biomol Screen15, 928-936. PubMed  Europe PubMed DOI  A
  288. Nuss,J.E., Dong,Y., Wanner,L.M., Ruthel,G., Wipf,P., Gussio,R., Vennerstrom,J.L., Bavari,S. and Burnett,J.C.
    Pharmacophore refinement guides the rational design of nanomolar-range inhibitors of the Botulinum neurotoxin serotype A metalloprotease
    ACS Med Chem Lett1, 301-305. PubMed  Europe PubMed DOI  I
  289. Pang,Y.P., Davis,J., Wang,S., Park,J.G., Nambiar,M.P., Schmidt,J.J. and Millard,C.B.
    Small molecules showing significant protection of mice against botulinum neurotoxin serotype A
    PLoS ONE5, e10129-e10129. PubMed  Europe PubMed DOI  I
  290. Pickett,A.
    Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects
    BioDrugs24, 173-182. PubMed  Europe PubMed DOI
  291. Raphael,B.H., Choudoir,M.J., Luquez,C., Fernandez,R. and Maslanka,S.E.
    Sequence diversity of genes encoding botulinum neurotoxin type F
    Appl Environ Microbiol76, 4805-4812. PubMed  Europe PubMed DOI
  292. Rowe,B., Schmidt,J.J., Smith,L.A. and Ahmed,S.A.
    Rapid product analysis and increased sensitivity for quantitative determinations of botulinum neurotoxin proteolytic activity
    Anal Biochem396, 188-193. PubMed  Europe PubMed DOI  A
  293. Saunders,M.J., Graves,S.W., Sklar,L.A., Oprea,T.I. and Edwards,B.S.
    High-throughput multiplex flow cytometry screening for botulinum neurotoxin type A light chain protease inhibitors
    Assay Drug Dev Technol8, 37-46. PubMed  Europe PubMed DOI  I
  294. Silhar,P., Capkova,K., Salzameda,N.T., Barbieri,J.T., Hixon,M.S. and Janda,K.D.
    Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors
    J Am Chem Soc132, 2868-2869. PubMed  Europe PubMed DOI  I
  295. Stowe,G.N., Silhar,P., Hixon,M.S., Silvaggi,N.R., Allen,K.N., Moe,S.T., Jacobson,A.R., Barbieri,J.T. and Janda,K.D.
    Chirality holds the key for potent inhibition of the Botulinum neurotoxin serotype A protease
    Org Lett12, 756-759. PubMed  Europe PubMed DOI  I
  296. Strotmeier,J., Lee,K., Volker,A.K., Mahrhold,S., Zong,Y., Zeiser,J., Zhou,J., Pich,A., Bigalke,H., Binz,T., Rummel,A. and Jin,R.
    Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner
    Biochem J431, 207-216. PubMed  Europe PubMed DOI
  297. Thanongsaksrikul,J., Srimanote,P., Maneewatch,S., Choowongkomon,K., Tapchaisri,P., Makino,S., Kurazono,H. and Chaicumpa,W.
    A VHH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A
    J Biol Chem285, 9657-9666. PubMed  Europe PubMed DOI
  298. Thyagarajan,B., Potian,J.G., Garcia,C.C., Hognason,K., Capkova,K., Moe,S.T., Jacobson,A.R., Janda,K.D. and McArdle,J.J.
    Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions
    Neuropharmacology58, 1189-1198. PubMed  Europe PubMed DOI  I
  299. Wang,H.H., Riding,S., Lindo,P. and Singh,B.R.
    Endopeptidase activities of Botulinum neurotoxin type B complex, holotoxin, and light chain
    Appl Environ Microbiol76, 6658-6663. PubMed  Europe PubMed DOI
    300. 2009
  300. Agarwal,R., Schmidt,J.J., Stafford,R.G. and Swaminathan,S.
    Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F
    Nat Struct Mol Biol16, 789-794. PubMed  Europe PubMed DOI  P  S
  301. Baumann,L., Brandt,F.S., Kane,M.A. and Donofrio,L.M.
    An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines
    Aesthet Surg J29, S57-S65. PubMed  Europe PubMed DOI
  302. Binz,T. and Rummel,A.
    Cell entry strategy of clostridial neurotoxins
    J Neurochem109, 1584-1595. PubMed  Europe PubMed DOI
  303. Brunger,A.T. and Rummel,A.
    Receptor and substrate interactions of clostridial neurotoxins
    Toxicon54, 550-560. PubMed  Europe PubMed DOI
  304. Burnett,J.C., Wang,C., Nuss,J.E., Nguyen,T.L., Hermone,A.R., Schmidt,J.J., Gussio,R., Wipf,P. and Bavari,S.
    Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease
    Bioorg Med Chem Lett19, 5811-5813. PubMed  Europe PubMed DOI  I
  305. Caleo,M., Antonucci,F., Restani,L. and Mazzocchio,R.
    A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?
    J Neurochem109, 15-24. PubMed  Europe PubMed DOI
  306. Capkova,K., Salzameda,N.T. and Janda,K.D.
    Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins
    Toxicon54, 575-582. PubMed  Europe PubMed DOI  I
  307. Carter,A.T., Paul,C.J., Mason,D.R., Twine,S.M., Alston,M.J., Logan,S.M., Austin,J.W. and Peck,M.W.
    Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum
    BMC Genomics10, 115-115. PubMed  Europe PubMed DOI
  308. Chen,S. and Barbieri,J.T.
    Engineering botulinum neurotoxin to extend therapeutic intervention
    Proc Natl Acad Sci U S A106, 9180-9184. PubMed  Europe PubMed DOI  U
  309. Evans,E.R., Skipper,P.J. and Shone,C.C.
    An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin
    J Appl Microbiol107, 1384-1391. PubMed  Europe PubMed DOI
  310. Hasani,L., Ranjbar,B., Tavallaie,M. and Sadeghizadeh,M.
    Identification of a molten globule like state in HC-N fragment of botulinum neurotoxin a: shedding light on the poorly-known features of a conserved sub-domain
    Protein Pept Lett16, 660-663. PubMed  Europe PubMed DOI
  311. Henkel,J.S., Jacobson,M., Tepp,W., Pier,C., Johnson,E.A. and Barbieri,J.T.
    Catalytic properties of Botulinum neurotoxin subtypes A3 and A4
    Biochemistry48, 2522-2528. PubMed  Europe PubMed DOI
  312. Hill,K.K., Xie,G., Foley,B.T., Smith,T.J., Munk,A.C., Bruce,D., Smith,L.A., Brettin,T.S. and Detter,J.C.
    Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains
    BMC Biol7, 66-66. PubMed  Europe PubMed DOI
  313. Jewell,M.L. and Monheit,G.D.
    An overview of clinical trial data on a new formulation of botulinum neurotoxin type A
    Aesthet Surg J29, S31-S33. PubMed  Europe PubMed DOI
  314. Koussoulakos,S.
    Botulinum neurotoxin: the ugly duckling
    Eur Neurol61, 331-342. PubMed  Europe PubMed DOI  V
  315. Kumaran,D., Eswaramoorthy,S., Furey,W., Navaza,J., Sax,M. and Swaminathan,S.
    Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation
    J Mol Biol386, 233-245. PubMed  Europe PubMed DOI  S
  316. Lai,H., Feng,M., Roxas-Duncan,V., Dakshanamurthy,S., Smith,L.A. and Yang,D.C.
    Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition
    Arch Biochem Biophys491, 75-84. PubMed  Europe PubMed DOI  I
  317. Lebrun,I., Marques-Porto,R., Pereira,A.S., Pereira,A. and Perpetuo,E.A.
    Bacterial toxins: an overview on bacterial proteases and their action as virulence factors
    Mini Rev Med Chem9, 820-828. PubMed  Europe PubMed DOI  V
  318. Miyata,K., Yoneyama,T., Suzuki,T., Kouguchi,H., Inui,K., Niwa,K., Watanabe,T. and Ohyama,T.
    Expression and stability of the nontoxic component of the botulinum toxin complex
    Biochem Biophys Res Commun384, 126-130. PubMed  Europe PubMed DOI
  319. Moe,S.T., Thompson,A.B., Smith,G.M., Fredenburg,R.A., Stein,R.L. and Jacobson,A.R.
    Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs
    Bioorg Med Chem17, 3072-3079. PubMed  Europe PubMed DOI  I
  320. Montal,M.
    Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel
    Toxicon54, 565-569. PubMed  Europe PubMed DOI
  321. Muraro,L., Tosatto,S., Motterlini,L., Rossetto,O. and Montecucco,C.
    The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane
    Biochem Biophys Res Commun380, 76-80. PubMed  Europe PubMed DOI
  322. Nishiyama,Y., Yokoyama,T., Tomizawa,K., Okamura,K., Yamamoto,Y., Matsui,H., Oguma,K., Nagai,A. and Kumon,H.
    Effects of purified newly developed botulinum neurotoxin type A in rat prostate
    Urology74, 436-439. PubMed  Europe PubMed DOI
  323. Pang,Y.P., Vummenthala,A., Mishra,R.K., Park,J.G., Wang,S., Davis,J., Millard,C.B. and Schmidt,J.J.
    Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design
    PLoS ONE4, e7730-e7730. PubMed  Europe PubMed DOI  I
  324. Peck,M.W.
    Biology and genomic analysis of Clostridium botulinum
    Adv Microb Physiol55, 183-265. PubMed  Europe PubMed DOI
  325. Pires-Alves,M., Ho,M., Aberle,K.K., Janda,K.D. and Wilson,B.A.
    Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity
    Toxicon53, 392-399. PubMed  Europe PubMed DOI  A
  326. Poras,H., Ouimet,T., Orng,S.V., Fournie-Zaluski,M.C., Popoff,M.R. and Roques,B.P.
    Detection and quantification of botulinum neurotoxin type A by a novel rapid in vitro fluorimetric assay
    Appl Environ Microbiol75, 4382-4390. PubMed  Europe PubMed DOI  A
  327. Roxas-Duncan,V., Enyedy,I., Montgomery,V.A., Eccard,V.S., Carrington,M.A., Lai,H., Gul,N., Yang,D.C. and Smith,L.A.
    Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A
    Antimicrobial Agents Chemother53, 3478-3486. PubMed  Europe PubMed DOI  I
  328. Rusnak,J.M. and Smith,L.A.
    Botulinum neurotoxin vaccines: past history and recent developments
    Hum Vaccin5, 794-805. PubMed  Europe PubMed
  329. Salzameda,N.T., Barbieri,J.T. and Janda,K.D.
    Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors
    Bioorg Med Chem Lett19, 5848-5850. PubMed  Europe PubMed DOI  A
  330. Shi,X., Garcia,G.E., Neill,R.J. and Gordon,R.K.
    TCEP treatment reduces proteolytic activity of BoNT/B in human neuronal SHSY-5Y cells
    J Cell Biochem107, 1021-1030. PubMed  Europe PubMed DOI
  331. Sun,S., Ossandon,M., Kostov,Y. and Rasooly,A.
    Lab-on-a-chip for botulinum neurotoxin A (BoNT-A) activity analysis
    Lab Chip9, 3275-3281. PubMed  Europe PubMed DOI  A
  332. Toth,S.I., Smith,L.A. and Ahmed,S.A.
    Extreme sensitivity of botulinum neurotoxin domains towards mild agitation
    J Pharm Sci98, 3302-3311. PubMed  Europe PubMed DOI
  333. Trollet,C., Pereira,Y., Burgain,A., Litzler,E., Mezrahi,M., Seguin,J., Manich,M., Popoff,M.R., Scherman,D. and Bigey,P.
    Generation of high-titer neutralizing antibodies against Botulinum toxins A, B, and E by DNA electrotransfer
    Infect Immun77, 2221-2229. PubMed  Europe PubMed DOI
  334. Webb,R.P., Smith,T.J., Wright,P., Brown,J. and Smith,L.A.
    Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3
    Vaccine27, 4490-4497. PubMed  Europe PubMed DOI
  335. Wortzman,M.S. and Pickett,A.
    The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use
    Aesthet Surg J29, S34-S42. PubMed  Europe PubMed DOI
  336. Zhou,H., Zhou,B., Pellett,S., Johnson,E.A. and Janda,K.D.
    Selection and characterization of a human monoclonal neutralizing antibody for Clostridium botulinum neurotoxin serotype B
    Bioorg Med Chem Lett19, 662-664. PubMed  Europe PubMed DOI
    337. 2008
  337. Agarwal,R. and Swaminathan,S.
    SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E
    J Biol Chem283, 25944-25951. PubMed  Europe PubMed DOI  S
  338. Alajbegovic,A., Alajbegovic,S. and Resic,H.
    [Mechanism of therapy effects by botulinum neurotoxin]
    Med Arch62, 53-55. PubMed  Europe PubMed
  339. Capkova,K., Hixon,M.S., McAllister,L.A. and Janda,K.D.
    Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations
    Chem Commun (Camb)2008, 3525-3527. PubMed  Europe PubMed DOI  A  I
  340. Chen,S., Hall,C. and Barbieri,J.T.
    Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin
    J Biol Chem283, 21153-21159. PubMed  Europe PubMed DOI  P
  341. Fischer,A., Garcia-Rodriguez,C., Geren,I., Lou,J., Marks,J.D., Nakagawa,T. and Montal,M.
    Molecular architecture of Botulinum neurotoxin E revealed by single particle electron microscopy
    J Biol Chem283, 3997-4003. PubMed  Europe PubMed DOI  S
  342. Hines,H.B., Kim,A.D., Stafford,R.G., Badie,S.S., Brueggeman,E.E., Newman,D.J. and Schmidt,J.J.
    Use of a recombinant fluorescent substrate with cleavage sites for all Botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E
    Appl Environ Microbiol74, 653-659. PubMed  Europe PubMed DOI  A  P
  343. Johnson,S.L., Chen,L.H., Harbach,R., Sabet,M., Savinov,A., Cotton,N.J., Strongin,A., Guiney,D. and Pellecchia,M.
    Rhodanine derivatives as selective protease inhibitors against bacterial toxins
    Chem Biol Drug Des71, 131-139. PubMed  Europe PubMed DOI  I
  344. Kumaran,D., Rawat,R., Ludivico,M.L., Ahmed,S.A. and Swaminathan,S.
    Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A
    J Biol Chem283, 18883-18891. PubMed  Europe PubMed DOI  S  I
  345. Rasooly,R., Stanker,L.H., Carter,J.M., Do,P.M., Cheng,L.W., He,X. and Brandon,D.L.
    Detection of botulinum neurotoxin-A activity in food by peptide cleavage assay
    Int J Food Microbiol126, 135-139. PubMed  Europe PubMed DOI  A
  346. Rawat,R., Ashraf Ahmed,S. and Swaminathan,S.
    High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to monitor its proteolytic activity
    Protein Expr Purif60, 165-169. PubMed  Europe PubMed DOI  A  E
  347. Sikorra,S., Henke,T., Galli,T. and Binz,T.
    Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins
    J Biol Chem283, 21145-21152. PubMed  Europe PubMed DOI
  348. Silvaggi,N.R., Wilson,D., Tzipori,S. and Allen,K.N.
    Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex
    Biochemistry47, 5736-5745. PubMed  Europe PubMed DOI  S
  349. Wang,J., Meng,J., Lawrence,G.W., Zurawski,T.H., Sasse,A., Bodeker,M.O., Gilmore,M.A., Fernandez-Salas,E., Francis,J., Steward,L.E., Aoki,K.R. and Dolly,J.O.
    Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics
    J Biol Chem283, 16993-17002. PubMed  Europe PubMed DOI
  350. Wohlfarth,K., Schwandt,I., Wegner,F., Jurgens,T., Gelbrich,G., Wagner,A., Bogdahn,U. and Schulte-Mattler,W.
    Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study
    J Neurol255, 1932-1939. PubMed  Europe PubMed DOI  U
  351. Zuniga,J.E., Schmidt,J.J., Fenn,T., Burnett,J.C., Arac,D., Gussio,R., Stafford,R.G., Badie,S.S., Bavari,S. and Brunger,A.T.
    A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate
    Structure16, 1588-1597. PubMed  Europe PubMed DOI  I
    352. 2007
  352. Burnett,J.C., Ruthel,G., Stegmann,C.M., Panchal,R.G., Nguyen,T.L., Hermone,A.R., Stafford,R.G., Lane,D.J., Kenny,T.A., McGrath,C.F., Wipf,P., Stahl,A.M., Schmidt,J.J., Gussio,R., Brunger,A.T. and Bavari,S.
    Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons
    J Biol Chem282, 5004-5014. PubMed  Europe PubMed DOI  S  I
  353. Capkova,K., Yoneda,Y., Dickerson,T.J. and Janda,K.D.
    Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors
    Bioorg Med Chem Lett17, 6463-6466. PubMed  Europe PubMed DOI  I
  354. Fischer,A. and Montal,M.
    Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes
    J Biol Chem282, 29604-29611. PubMed  Europe PubMed DOI
  355. Garcia-Rodriguez,C., Levy,R., Arndt,J.W., Forsyth,C.M., Razai,A., Lou,J., Geren,I., Stevens,R.C. and Marks,J.D.
    Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin
    Nat Biotechnol25, 107-116. PubMed  Europe PubMed DOI
  356. Jin,R., Sikorra,S., Stegmann,C.M., Pich,A., Binz,T. and Brunger,A.T.
    Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity
    Biochemistry46, 10685-10693. PubMed  Europe PubMed DOI
  357. Silvaggi,N.R., Boldt,G.E., Hixon,M.S., Kennedy,J.P., Tzipori,S., Janda,K.D. and Allen,K.N.
    Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility
    Chem Biol14, 533-542. PubMed  Europe PubMed DOI  S  I
  358. Tang,J., Park,J.G., Millard,C.B., Schmidt,J.J. and Pang,Y.P.
    Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A
    PLoS ONE2, e761-e761. PubMed  Europe PubMed DOI  I
    359. 2006
  359. Arndt,J.W., Jacobson,M.J., Abola,E.E., Forsyth,C.M., Tepp,W.H., Marks,J.D., Johnson,E.A. and Stevens,R.C.
    A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4
    J Mol Biol362, 733-742. PubMed  Europe PubMed DOI
  360. [YEAR:14-3-2006]Arndt,J.W., Chai,Q., Christian,T. and Stevens,R.C.
    Structure of Botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity
    Biochemistry45, 3255-3262. PubMed  Europe PubMed DOI  S
  361. [YEAR:13-4-2006]Boldt,G.E., Kennedy,J.P. and Janda,K.D.
    Identification of a potent botulinum neurotoxin A protease inhibitor using in situ lead identification chemistry
    Org Lett8, 1729-1732. PubMed  Europe PubMed DOI  I
  362. Boldt,G.E., Eubanks,L.M. and Janda,K.D.
    Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model
    Chem Commun (Camb)2006, 3063-3065. PubMed  Europe PubMed DOI  I
  363. Chai,Q., Arndt,J.W., Dong,M., Tepp,W.H., Johnson,E.A., Chapman,E.R. and Stevens,R.C.
    Structural basis of cell surface receptor recognition by botulinum neurotoxin B
    Nature444, 1096-1100. PubMed  Europe PubMed DOI  S
  364. Couesnon,A., Raffestin,S. and Popoff,M.R.
    Expression of botulinum neurotoxins A and E, and associated non-toxin genes, during the transition phase and stability at high temperature: analysis by quantitative reverse transcription-PCR
    Microbiology (Reading)152, 759-770. PubMed  Europe PubMed DOI  E
  365. DasGupta,B.R.
    Botulinum neurotoxins: perspective on their existence and as polyproteins harboring viral proteases
    J Gen Appl Microbiol52, 1-8. PubMed  Europe PubMed DOI
  366. Dolly,J.O. and Aoki,K.R.
    The structure and mode of action of different botulinum toxins
    Eur J Neurol13 Suppl 4, 1-9. PubMed  Europe PubMed DOI
  367. Fu,Z., Chen,S., Baldwin,M.R., Boldt,G.E., Crawford,A., Janda,K.D., Barbieri,J.T. and Kim,J.J.
    Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate
    Biochemistry45, 8903-8911. PubMed  Europe PubMed DOI  S
  368. [YEAR:4-5-2006]Lim,E.C., Oh,V.M., Ong,B.K., Chow,A.W. and Seet,R.C.
    Where has all the botox gone? (How) will we ever learn... Using monoclonal antibodies to track botulinum toxin
    Med Hypotheses67, 440-446. PubMed  Europe PubMed DOI  V
  369. Oliver,M., Macdonald,J. and Rajwani,M.
    The use of botulinum neurotoxin type A (Botox) for headaches: a case review
    JCCA J Can Chiropr Assoc50, 263-270. PubMed  Europe PubMed
  370. [YEAR:30-9-2006]Park,J.G., Sill,P.C., Makiyi,E.F., Garcia-Sosa,A.T., Millard,C.B., Schmidt,J.J. and Pang,Y.P.
    Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A
    Bioorg Med Chem14, 395-408. PubMed  Europe PubMed DOI  I
  371. Sikorra,S., Henke,T., Swaminathan,S., Galli,T. and Binz,T.
    Identification of the amino acid residues rendering TI-VAMP insensitive toward botulinum neurotoxin B
    J Mol Biol357, 574-582. PubMed  Europe PubMed DOI
    372. 2005
  372. Agarwal,R., Binz,T. and Swaminathan,S.
    Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design
    Biochemistry44, 11758-11765. PubMed  Europe PubMed DOI  S
  373. Agarwal,R., Binz,T. and Swaminathan,S.
    Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme
    Biochemistry44, 8291-8302. PubMed  Europe PubMed DOI
  374. Arndt,J.W., Yu,W., Bi,F. and Stevens,R.C.
    Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition
    Biochemistry44, 9574-9580. PubMed  Europe PubMed DOI  S
  375. Montecucco,C. and Molgo,J.
    Botulinal neurotoxins: revival of an old killer
    Curr Opin Pharmacol5, 274-279. PubMed  Europe PubMed DOI
  376. Sutton,J.M., Wayne,J., Scott-Tucker,A., O'Brien,S.M., Marks,P.M., Alexander,F.C., Shone,C.C. and Chaddock,J.A.
    Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications
    Protein Expr Purif40, 31-41. PubMed  Europe PubMed DOI
    377. 2004
  377. Agarwal,R., Eswaramoorthy,S., Kumaran,D., Dunn,J.J. and Swaminathan,S.
    Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain
    Protein Expr Purif34, 95-102. PubMed  Europe PubMed DOI
  378. Agarwal,R., Eswaramoorthy,S., Kumaran,D., Binz,T. and Swaminathan,S.
    Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212 - >Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway
    Biochemistry43, 6637-6644. PubMed  Europe PubMed DOI  S
  379. Aoki,K.R.
    Botulinum toxin: a successful therapeutic protein
    Curr Med Chem11, 3085-3092. PubMed  Europe PubMed  V
  380. Baldwin,M.R., Bradshaw,M., Johnson,E.A. and Barbieri,J.T.
    The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability
    Protein Expr Purif37, 187-195. PubMed  Europe PubMed DOI
  381. [YEAR:1-6-2004]Blommaert,A., Turcaud,S., Anne,C. and Roques,B.P.
    Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity
    Bioorg Med Chem12, 3055-3062. PubMed  Europe PubMed DOI  I
  382. [YEAR:16-12-2004]Breidenbach,M.A. and Brunger,A.T.
    Substrate recognition strategy for botulinum neurotoxin serotype A
    Nature432, 925-929. PubMed  Europe PubMed DOI  S
  383. Carruthers,J., Fagien,S. and Matarasso,S.L.
    Consensus recommendations on the use of botulinum toxin type A in facial aesthetics
    Plast Reconstr Surg114, 1S-22S. PubMed  Europe PubMed DOI
  384. Chaddock,J.A., Purkiss,J.R., Alexander,F.C., Doward,S., Fooks,S.J., Friis,L.M., Hall,Y.H., Kirby,E.R., Leeds,N., Moulsdale,H.J., Dickenson,A., Green,G.M., Rahman,W., Suzuki,R., Duggan,M.J., Quinn,C.P., Shone,C.C. and Foster,K.A.
    Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain
    Mov Disord19 Suppl 8, S42-S47. PubMed  Europe PubMed DOI
  385. Erbguth,F.J.
    Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin
    Mov Disord19 Suppl 8, S2-S6. PubMed  Europe PubMed DOI
  386. Eswaramoorthy,S., Kumaran,D., Keller,J. and Swaminathan,S.
    Role of metals in the biological activity of Clostridium botulinum neurotoxins
    Biochemistry43, 2209-2216. PubMed  Europe PubMed DOI  S
  387. [YEAR:2-3-2004]Fernandez-Salas,E., Steward,L.E., Ho,H., Garay,P.E., Sun,S.W., Gilmore,M.A., Ordas,J.V., Wang,J., Francis,J. and Aoki,K.R.
    Plasma membrane localization signals in the light chain of botulinum neurotoxin
    Proc Natl Acad Sci U S A101, 3208-3213. PubMed  Europe PubMed DOI
  388. Francisco,G.E.
    Botulinum toxin: dosing and dilution
    Am J Phys Med Rehabil83, S30-S37. PubMed  Europe PubMed DOI
  389. Gul,N., Ahmed,S.A. and Smith,L.A.
    Inhibition of the protease activity of the light chain of type A botulinum neurotoxin by aqueous extract from stinging nettle (Urtica dioica) leaf
    Basic Clin Pharmacol Toxicol95, 215-219. PubMed  Europe PubMed DOI
  390. [YEAR:3-12-2004]Ibanez,C., Blanes-Mira,C., Fernandez-Ballester,G., Planells-Cases,R. and Ferrer-Montiel,A.
    Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation
    FEBS Lett578, 121-127. PubMed  Europe PubMed DOI
  391. Montecucco,C., Rossetto,O. and Schiavo,G.
    Presynaptic receptor arrays for clostridial neurotoxins
    Trends Microbiol12, 442-446. PubMed  Europe PubMed DOI
  392. Montecucco,C. and Tonello,F.
    Bontoxilysins
    [ISSN:0-12-079610-4]2, 451-456.  V
  393. Naumann,M. and Jankovic,J.
    Safety of botulinum toxin type A: a systematic review and meta-analysis
    Curr Med Res Opin20, 981-990. PubMed  Europe PubMed DOI
  394. [YEAR:4-5-2004]Segelke,B., Knapp,M., Kadkhodayan,S., Balhorn,R. and Rupp,B.
    Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity
    Proc Natl Acad Sci U S A101, 6888-6893. PubMed  Europe PubMed DOI  S
  395. [YEAR:27-4-2004]Sharma,S.K. and Singh,B.R.
    Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins
    Biochemistry43, 4791-4798. PubMed  Europe PubMed DOI
  396. Simpson,L.L.
    Identification of the major steps in botulinum toxin action
    Annu Rev Pharmacol Toxicol44, 167-193. PubMed  Europe PubMed DOI
  397. Sukonpan,C., Oost,T., Goodnough,M., Tepp,W., Johnson,E.A. and Rich,D.H.
    Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease
    J Pept Res63, 181-193. PubMed  Europe PubMed DOI  I
  398. Swaminathan,S., Eswaramoorthy,S. and Kumaran,D.
    Structure and enzymatic activity of botulinum neurotoxins
    Mov Disord19 Suppl 8, S17-S22. PubMed  Europe PubMed DOI
  399. Ting,P.T. and Freiman,A.
    The story of Clostridium botulinum: from food poisoning to Botox
    Clin Med (Lond)4, 258-261. PubMed  Europe PubMed
    400. 2003
  400. [YEAR:10-10-2003]Burnett,J.C., Schmidt,J.J., Stafford,R.G., Panchal,R.G., Nguyen,T.L., Hermone,A.R., Vennerstrom,J.L., McGrath,C.F., Lane,D.J., Sausville,E.A., Zaharevitz,D.W., Gussio,R. and Bavari,S.
    Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity
    Biochem Biophys Res Commun310, 84-93. PubMed  Europe PubMed DOI  I
  401. Koriazova,L.K. and Montal,M.
    Translocation of botulinum neurotoxin light chain protease through the heavy chain channel
    Nat Struct Biol10, 13-18. PubMed  Europe PubMed DOI
  402. Oost,T., Sukonpan,C., Brewer,M., Goodnough,M., Tepp,W., Johnson,E.A. and Rich,D.H.
    Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease
    Biopolymers71, 602-619. PubMed  Europe PubMed DOI  I
  403. Schmidt,J.J. and Stafford,R.G.
    Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F
    Appl Environ Microbiol69, 297-303. PubMed  Europe PubMed DOI  A
    404. 2002
  404. [YEAR:12-2-2002]Binz,T., Bade,S., Rummel,A., Kollewe,A. and Alves,J.
    Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization
    Biochemistry41, 1717-1723. PubMed  Europe PubMed DOI
  405. Chaddock,J.A., Herbert,M.H., Ling,R.J., Alexander,F.C., Fooks,S.J., Revell,D.F., Quinn,C.P., Shone,C.C. and Foster,K.A.
    Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A
    Protein Expr Purif25, 219-228. PubMed  Europe PubMed DOI
  406. Eswaramoorthy,S., Kumaran,D. and Swaminathan,S.
    A novel mechanism for Clostridium botulinum neurotoxin inhibition
    Biochemistry41, 9795-9802. PubMed  Europe PubMed DOI  S  I
  407. [YEAR:18-12-2002]Schmidt,J.J. and Stafford,R.G.
    A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity
    FEBS Lett532, 423-426. PubMed  Europe PubMed DOI  I
    408. 2001
  408. Ahmed,S.A., Byrne,M.P., Jensen,M., Hines,H.B., Brueggemann,E. and Smith,L.A.
    Enzymatic autocatalysis of botulinum A neurotoxin light chain
    J Protein Chem20, 221-231. PubMed  Europe PubMed DOI
  409. [YEAR:15-4-2001]Anne,C., Cornille,F., Lenoir,C. and Roques,B.P.
    High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity
    Anal Biochem291, 253-261. PubMed  Europe PubMed DOI  A
  410. Blanes-Mira,C., Ibanez,C., Fernandez-Ballester,G., Planells-Cases,R., Perez-Paya,E. and Ferrer-Montiel,A.
    Thermal stabilization of the catalytic domain of botulinum neurotoxin E by phosphorylation of a single tyrosine residue
    Biochemistry40, 2234-2242. PubMed  Europe PubMed DOI
  411. Brashear,A.
    Botulinum toxin type B: a new injectable treatment for cervical dystonia
    Expert Opin Investig Drugs10, 2191-2199. PubMed  Europe PubMed DOI
  412. [YEAR:17-4-2001]Cai,S.W. and Singh,B.R.
    A correlation between differential structural features and the degree of endopeptidase activity of type A botulinum neurotoxin in aqueous solution
    Biochemistry40, 4693-4702. PubMed  Europe PubMed DOI
  413. [YEAR:18-12-2001]Cai,S.W. and Singh,B.R.
    Role of the disulfide cleavage induced molten globule state of type A botulinum neurotoxin in its endopeptidase activity
    Biochemistry40, 15327-15333. PubMed  Europe PubMed DOI
  414. Prabakaran,S., Tepp,W. and DasGupta,B.R.
    Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin
    Toxicon39, 1515-1531. PubMed  Europe PubMed DOI
  415. [YEAR:16-11-2001]Rigoni,M., Caccin,P., Johnson,E.A., Montecucco,C. and Rossetto,O.
    Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A
    Biochem Biophys Res Commun288, 1231-1237. PubMed  Europe PubMed DOI
  416. [YEAR:1-9-2001]Schmidt,J.J., Stafford,R.G. and Millard,C.B.
    High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F
    Anal Biochem296, 130-137. PubMed  Europe PubMed DOI  A
    417. 2000
  417. Ahmed,S.A. and Smith,L.A.
    Light chain of botulinum a neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active
    J Protein Chem19, 475-487. PubMed  Europe PubMed DOI
  418. Chaddock,J.A., Purkiss,J.R., Friis,L.M., Broadbridge,J.D., Duggan,M.J., Fooks,S.J., Shone,C.C., Quinn,C.P. and Foster,K.A.
    Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A
    Infect Immun68, 2587-2593. PubMed  Europe PubMed DOI
  419. Comella,C.L., Jankovic,J. and Brin,M.F.
    Use of botulinum toxin type A in the treatment of cervical dystonia
    Neurology55, S15-S21. PubMed  Europe PubMed
  420. Hanson,M.A. and Stevens,R.C.
    Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution
    Nat Struct Biol7, 687-692. PubMed  Europe PubMed DOI  S
  421. Humeau,Y., Doussau,F., Grant,N.J. and Poulain,B.
    How botulinum and tetanus neurotoxins block neurotransmitter release
    Biochimie82, 427-446. PubMed  Europe PubMed DOI
  422. Kadkhodayan,S., Knapp,M.S., Schmidt,J.J., Fabes,S.E., Rupp,B. and Balhorn,R.
    Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A
    Protein Expr Purif19, 125-130. PubMed  Europe PubMed DOI
  423. [YEAR:30-5-2000]Li,L. and Singh,B.R.
    Spectroscopic analysis of pH-induced changes in the molecular features of type a botulinum neurotoxin light chain
    Biochemistry39, 6466-6474. PubMed  Europe PubMed DOI
  424. [YEAR:7-3-2000]Li,L., Binz,T., Niemann,H. and Singh,B.R.
    Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain
    Biochemistry39, 2399-2405. PubMed  Europe PubMed DOI
  425. [YEAR:29-8-2000]Li,L. and Singh,B.R.
    Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure
    Biochemistry39, 10581-10586. PubMed  Europe PubMed DOI
  426. Schiavo,G., Matteoli,M. and Montecucco,C.
    Neurotoxins affecting neuroexocytosis
    Physiol Rev80, 717-766. PubMed  Europe PubMed  V
  427. Swaminathan,S. and Eswaramoorthy,S.
    Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B
    Nat Struct Biol7, 693-699. PubMed  Europe PubMed DOI
    428. 1999
  428. Adler,M., Nicholson,J.D., Starks,D.F., Kane,C.T., Cornille,F. and Hackley,B.E., Jr.
    Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity
    J Appl Toxicol19 Suppl 1, S5-S11. PubMed  Europe PubMed DOI  I
  429. [YEAR:25-5-1999]Cai,S., Sarkar,H.K. and Singh,B.R.
    Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol
    Biochemistry38, 6903-6910. PubMed  Europe PubMed DOI
  430. Cornille,F. and Roques,B.P.
    [Tetanus and botulinum toxins are zinc metallopeptidases: molecular mechanisms and inhibition of their neurotoxicity]
    J Soc Biol193, 509-516. PubMed  Europe PubMed  I
  431. Gaines Das,R.E., Heath,A.B., Martin,H. and Sesardic,D.
    Validation of in vitro assays for botulinum toxin: a case study
    Dev Biol Stand101, 267-276. PubMed  Europe PubMed  A
  432. Garcia,G.E., Moorad,D.R. and Gordon,R.K.
    Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity in vitro
    J Appl Toxicol19 Suppl 1, S19-S22. PubMed  Europe PubMed DOI
  433. [YEAR:3-9-1999]Lacy,D.B. and Stevens,R.C.
    Sequence homology and structural analysis of the clostridial neurotoxins
    J Mol Biol291, 1091-1104. PubMed  Europe PubMed DOI  S
  434. Li,L. and Singh,B.R.
    Structure-function relationship of clostridial neurotoxins
    J Toxicol Toxin Rev18, 95-112.
  435. Li,L. and Singh,B.R.
    High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain
    Protein Expr Purif17, 339-344. PubMed  Europe PubMed DOI  E
  436. Najib,A., Pelliccioni,P., Gil,C. and Aguilera,J.
    Clostridium neurotoxins influence serotonin uptake and release differently in rat brain synaptosomes
    J Neurochem72, 1991-1998. PubMed  Europe PubMed DOI
  437. [YEAR:28-2-1999]Pellizzari,R., Rossetto,O., Schiavo,G. and Montecucco,C.
    Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses
    Philos Trans R Soc Lond B Biol Sci354, 259-268. PubMed  Europe PubMed DOI
  438. Vaidyanathan,V.V., Yoshino,K., Jahnz,M., Dorries,C., Bade,S., Nauenburg,S., Niemann,H. and Binz,T.
    Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: Domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage
    J Neurochem72, 327-337. PubMed  Europe PubMed DOI
  439. Washbourne,P., Bortoletto,N., Graham,M.E., Wilson,M.C., Burgoyne,R.D. and Montecucco,C.
    Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis
    J Neurochem73, 2424-2433. PubMed  Europe PubMed DOI
  440. Wictome,M., Newton,K., Jameson,K., Hallis,B., Dunnigan,P., Mackay,E., Clarke,S., Taylor,R., Gaze,J., Foster,K. and Shone,C.
    Development of an in vitro bioassay for Clostridium botulinum type B neurotoxin in foods that is more sensitive than the mouse bioassay
    Appl Environ Microbiol65, 3787-3792. PubMed  Europe PubMed  A
  441. Wictome,M., Newton,K.A., Jameson,K., Dunnigan,P., Clarke,S., Gaze,J., Tauk,A., Foster,K.A. and Shone,C.C.
    Development of in vitro assays for the detection of botulinum toxins in foods
    FEMS Immunol Med Microbiol24, 319-323. PubMed  Europe PubMed DOI  A
    442. 1998
  442. Chen,F., Kuziemko,G.M. and Stevens,R.C.
    Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species
    Infect Immun66, 2420-2425. PubMed  Europe PubMed
  443. [YEAR:14-4-1998]Fu,F.N., Lomneth,R.B., Cai,S. and Singh,B.R.
    Role of zinc in the structure and toxic activity of botulinum neurotoxin
    Biochemistry37, 5267-5278. PubMed  Europe PubMed DOI
  444. Lacy,D.B., Tepp,W., Cohen,A.C., DasGupta,B.R. and Stevens,R.C.
    Crystal structure of botulinum neurotoxin type A and implications for toxicity
    Nat Struct Biol5, 898-902. PubMed  Europe PubMed DOI  S
  445. [YEAR:11-9-1998]Schmidt,J.J., Stafford,R.G. and Bostian,K.A.
    Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite
    FEBS Lett435, 61-64. PubMed  Europe PubMed DOI  I
    446. 1997
  446. Antharavally,B.S. and DasGupta,B.R.
    Covalent structure of botulinum neurotoxin type E: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains
    J Protein Chem16, 787-799. PubMed  Europe PubMed DOI
  447. Beecher,D.J. and DasGupta,B.R.
    Botulinum neurotoxin type A: limited proteolysis by endoproteinase Glu-C and alpha-chymotrypsin enhanced following reduction; identification of the cleaved sites and fragments
    J Protein Chem16, 701-712. PubMed  Europe PubMed DOI
  448. Deloye,F., Doussau,F. and Poulain,B.
    [Action mechanisms of botulinum neurotoxins and tetanus neurotoxins]
    C R Seances Soc Biol Fil191, 433-450. PubMed  Europe PubMed
  449. [YEAR:24-11-1997]Washbourne,P., Pellizzari,R., Baldini,G., Wilson,M.C. and Montecucco,C.
    Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis
    FEBS Lett418, 1-5. PubMed  Europe PubMed DOI
    450. 1996
  450. Hallis,B., James,B.A. and Shone,C.C.
    Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities
    J Clin Microbiol34, 1934-1938. PubMed  Europe PubMed  A
  451. Montecucco,C., Schiavo,G. and Rossetto,O.
    The mechanism of action of tetanus and botulinum neurotoxins
    Arch Toxicol Suppl18, 342-354. PubMed  Europe PubMed  V
  452. Tonello,F., Morante,S., Rossetto,O., Schiavo,G. and Montecucco,C.
    Tetanus and botulism neurotoxins: a novel group of zinc-endopeptidases
    Adv Exp Med Biol389, 251-260. PubMed  Europe PubMed
  453. Williamson,L.C., Halpern,J.L., Montecucco,C., Brown,J.E. and Neale,E.A.
    Clostridial neurotoxins and substrate proteolysis in intact neurons: Botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa
    J Biol Chem271, 7694-7699. PubMed  Europe PubMed
    454. 1995
  454. Schiavo,G. and Montecucco,C.
    Tetanus and botulism neurotoxins: isolation and assay
    Methods Enzymol248, 643-652. PubMed  Europe PubMed DOI  A  V
  455. Shone,C.C. and Tranter,H.S.
    Growth of clostridia and preparation of their neurotoxins
    Curr Top Microbiol Immunol195, 143-160. PubMed  Europe PubMed
    456. 1994
  456. East,A.K. and Collins,M.D.
    Conserved structure of genes encoding components of botulinum neurotoxin complex M and the sequence of the gene coding for the nontoxic component in nonproteolytic Clostridium botulinum type F
    Curr Microbiol29, 69-77. PubMed  Europe PubMed DOI
  457. Montecucco,C. and Schiavo,G.
    Mechanism of action of tetanus and botulinum neurotoxins
    Mol Microbiol13, 1-8. PubMed  Europe PubMed DOI
  458. Schiavo,G., Malizio,C., Trimble,W.S., Polverino de Laureto,P., Milan,G., Sugiyama,H., Johnson,E.A. and Montecucco,C.
    Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond
    J Biol Chem269, 20213-20216. PubMed  Europe PubMed  P
  459. [YEAR:29-4-1994]Yamasaki,S., Baumeister,A., Binz,T., Blasi,J., Link,E., Cornille,F., Roques,B., Fykse,E.M., Sudhof,T.C. and Jahn,R.
    Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin
    J Biol Chem269, 12764-12772. PubMed  Europe PubMed
    460. 1993
  460. Blasi,J., Chapman,E.R., Yamasaki,S., Binz,T., Niemann,H. and Jahn,R.
    Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin
    EMBO J12, 4821-4828. PubMed  Europe PubMed
  461. Blasi,J., Chapman,E.R., Link,E., Binz,T., Yamasaki,S., De Camilli,P., Sudhof,T.C., Niemann,H. and Jahn,R.
    Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
    Nature365, 160-163. PubMed  Europe PubMed DOI
  462. Montecucco,C. and Schiavo,G.
    Tetanus and botulism neurotoxins: a new group of zinc proteases
    Trends Biochem Sci18, 324-327. PubMed  Europe PubMed DOI
  463. [YEAR:29-11-1993]Schiavo,G., Santucci,A., DasGupta,B.R., Mehta,P.P., Jontes,J., Benfenati,F., Wilson,M.C. and Montecucco,C.
    Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds
    FEBS Lett335, 99-103. PubMed  Europe PubMed DOI
  464. [YEAR:5-6-1993]Schiavo,G., Shone,C.C., Rossetto,O., Alexander,F.C. and Montecucco,C.
    Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin
    J Biol Chem268, 11516-11519. PubMed  Europe PubMed
  465. [YEAR:15-11-1993]Schiavo,G., Rossetto,O., Catsicas,S., Polverino de Laureto,P., DasGupta,B.R., Benfenati,F. and Montecucco,C.
    Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E
    J Biol Chem268, 23784-23787. PubMed  Europe PubMed
    466. 1992
  466. Fujii,N., Kimura,K., Yashiki,T., Tsuzuki,K., Moriishi,K., Yokosawa,N., Syuto,B. and Oguma,K.
    Cloning and whole nucleotide sequence of the gene for the light chain component of Botulinum type E toxin from Clostridium butyricum strain BL6340 and Clostridium botulinum type E strain Mashike
    Microbiol Immunol36, 213-220. PubMed  Europe PubMed
  467. Fujii,N., Kimura,K., Yokosawa,N., Tsuzuki,K. and Oguma,K.
    A zinc-protease specific domain in botulinum and tetanus neurotoxins
    Toxicon30, 1486-1488. PubMed  Europe PubMed DOI
  468. Schiavo,G., Benfenati,F., Poulain,B., Rossetto,O., Polverino de Laureto,P., DasGupta,B.R. and Montecucco,C.
    Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin
    Nature359, 832-835. PubMed  Europe PubMed DOI
    469. 1989
  469. Scott,A.B.
    Clostridial toxin as therapeutic agents
    399-412.  U
    470. 1986
  470. [YEAR:6-11-1986]Penner,R., Neher,E. and Dreyer,F.
    Intracellularly injected tetanus toxin inhibits exocytosis in bovine adrenal chromaffin cells
    Nature324, 76-78. PubMed  Europe PubMed DOI
    471. 1982
  471. Gill,D.M.
    Bacterial toxins: a table of lethal amounts
    Microbiol Rev46, 86-94. PubMed  Europe PubMed

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use